W OLTORIAUS NULLUMUUS 20170290768A1 NI UHIMUNA UMU. ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2017/ 0290768 A1 BARZILAY et al . (43 ) Pub . Date : Oct. 12 , 2017 (54 ) COMPOSITIONS AND METHODS FOR B65D 81/ 32 (2006 .01 ) SELECTIVE GI TRACT DELIVERY A61K 36 /9068 ( 2006 .01 ) A23L 2 /52 (2006 . 01 ) (71 ) Applicant: VITAL BEVERAGES GLOBAL A23L 33 / 00 (2006 .01 ) INC . , Tortola (VG ) A61K 9 / 10 ( 2006 . 01 ) A61K 31/ 525 (2006 . 01) ( 72 ) Inventors: Amir BARZILAY , Kokhav Yair ( IL ) ; (52 ) U . S . CI. Dorit ROZNER , Gedera ( IL ) ??? . . . . A61K 9 /0095 ( 2013 .01 ) ; A61K 9 / 10 ( 2013 . 01 ) ; A61K 31 / 7004 ( 2013 .01 ) ; A61K (21 ) Appl. No. : 15 / 513, 672 9 / 5015 ( 2013 .01 ); A61K 9/ 5063 ( 2013 .01 ) ; A61K 9 /5047 ( 2013 .01 ) ; A61K 9 /501 (22 ) PCT Filed : Sep . 20 , 2015 ( 2013 .01 ); A61K 31 /525 ( 2013 . 01 ) ; A61K 9 /5052 ( 2013 .01 ) ; A61K 36 / 9068 (2013 .01 ) ; ( 86 ) PCT No. : PCT/ IL 2015 / 050951 A61K 9 / 0053 ( 2013 . 01 ) ; A23L 2 / 52 (2013 .01 ) ; $ 371 (c )( 1 ), A23L 33 /40 (2016 .08 ); B650 81/ 32 (2013 . 01 ); ( 2 ) Date : Mar . 23 , 2017 A23V 2002/ 00 (2013 . 01 ) Related U . S . Application Data ( 57 ) ABSTRACT ( 60 ) Provisional application No . 62/ 054 , 456 , filed on Sep . A composition -of - matter is provided . The present composi 24 , 2014 tion includes dietary supplements capable of reducing or reversing the negative effects of alcohol on motor and Publication Classification cognition , dietary supplements having anti - gastroparesis , (51 ) Int. Cl. antiemetic , analgesic and anti - inflammatory activities and / or A61K 9 /00 ( 2006 .01 ) dietary supplements capable of increasing alcohol catabo A61K 31 / 7004 ( 2006 . 01 ) lism and decreasing the level of toxic products of alcohol A61K 9 / 50 ( 2006 . 01 ) catabolism . Patent Application Publication Oct. 12 , 2017 Sheet 1 of 8 US 2017/ 0290768 A1

awa Arrrrrrrrrrsion Controssionpilanessettersionone to on stoonhotosinneroes .

Sainsorsetties it. Moreasteinatonioniotos

heeteollent

FIG . 1

FIG. 2 Patent Application Publication Oct. 12 , 2017 Sheet 2 of 8 US 2017 /0290768 A1

SCOREBUBBLEZ- *SPEEDBUBBLEZ

at 17:00204018'19: the

-- -- -SCOREBASELINE +SPEEDBASELINE 8 o o o o 0 = g 8 FIG.3

WWNO

AANoskon -4 .UTILIT

TIMESCOREBASELINESPEEDBASELINESCOREBUBBLEZSPEEDBUBBLEZ kooooooo -

-14 -14 -8 ??

17:0017:20 17:40 18:00 18:20118:40 19:0020 19: 19:401 Patent Application Publication Oct. 12 , 2017 Sheet 3 of 8 US 2017 / 0290768 A1

-

-#SCOREBUBBLEZ *SPEEDBUBBLEZ

--- *

'T17:001720401819:002040 --- -

-•SCOREBASELINE +SPEEDBASELINE FIG.4 ? ? ? •

TIMESCOREBASELINESPEEDBASELINECOREBUBBLEZSPEED

AA ER NN??

17:00 17:20 17:401 18:00 18:2018:40 19:00 19:20 19:40 Patent Application Publication Oct. 12 , 2017 Sheet 4 of 8 US 2017 /0290768 A1

-

-

- *SPEEDBUBBLEZ in-t- -SCOREBUBBLEZ

- °17:001720'40181820190019:30

--- -

-.SCOREBASELINE +SPEEDBASELINE FIG.5 s

NOCOCNAL

2. SPEEDBUBBLEZ|SCOREBASELINE

-

17:001 17:2017:40 18:00 18:2018:40 19:0019:20 19:40 Patent Application Publication Oct. 12 , 2017 Sheet 5 of 8 US 2017 /0290768 A1

-

-

-

- -+SCOREBUBBLEZ *SPEEDBUBBLEZ -

- 17:00'20401819:0020'40

-

-SCOREBASELINE +SPEEDBASELINE FIG.6

COOOOO TIMESCOREBASELINESPEEDSCOREBUBBLEZSPEED

TITUTI

17:0017:20 17:40 0018 : 18:2018:40 19:00 19:20 4019: Patent Application Publication Oct. 12 , 2017 Sheet 6 of 8 US 2017 /0290768 A1

RELATIVE RELESE % VITAMIN B2 COATED WITH ZEIN IN PH 1 . 1 RELATIVERELESE%83 Roofjoo

20 20 20 80 100 120 140 TIME - min FIG . 7

1 1 | |

-

- I V DO 2000 - - OOO > -

- - 08por ac - 2008.00008 0889889 gr900oogpopago& ABLB 1 -

/ / Til- - - Vi v

- IL | 1T | | | ? I ? i 1 50 MICRONS 55 MICRONS L J L - K

- - J 60 MICRONS 65 MICRONS FIG . 8A FIG . 8B Patent Application Publication Oct. 12, 2017 Sheet 7 of 8 US 2017 /0290768 A1

- w - - I n T . TIT . w w waren voor een many recorren te este . LE " ELIIL LEW A

WM MALL wwwwwww www . matamu

SE OSS 08686 wing -45MICRONS.SimoneSan FIG.9C FIG.10C O 60MICRONS 45MICRONS 55MICRONS onlara Ooo

wwwww h a t way proto wo wo w w ww www why www . www . Khat i uw ww A * . wwwwwwwww. ut

M W w dowo: cow www www mw swm w my www wytwy . www ww . mx .com w w ww .Www www . www , www www Ew :

trur www www wy wxwwwwwwwwwx www : ww www . waru -

witry byw w wwwwwwwwwwwwwwx www WATE

ZO 60MICRONS 75MICRONS FIG.9B 50MICRONS 60MICRONS FIG.10B

r L > win MARY WOW www. WILLmu...... realizamos nous vous remercie- -

ale w www com www w . towe w 4000 404 Mr Mw w we were ...... more inthe i r name on www mwema

h her . side ww w . m . www www www ww . Ww wWwwWw worow Will Wani. www . w . Xab i c with * X * ** * www ww . Ww Win www . .. . www. W per www . aw . www AO V ict w X W Sint with www www wie wir www

WY 880. 8 & o o 02 50MICRONS 70MICRONS FIG.9A 55MICRONS 65MICRONS FIG.10A

www. www w wwwwwwwww w w W w my . .. - . .

Y nemwww wwmonun severewww comes wwww the means w www www ww w w . wwwwwwwww hoe one or more video . . - - - Patent Application Publication Oct . 12, 2017 Sheet 8 of 8 US 2017/ 0290768 A1

I 1 I X 1 1 1

. MICRONS45 55MICRONS 65MICRONS 11DFIG.

www www what com . 1 per manente internet to receive serio us !L 1 U ! Wit Wed ww ww www ww w ww Wwwwwwwwwwwwwwwwwwwwwwwwww1 11 il *

. mm ww - nowe com come more or one come - www mwen www . www www www www www www .m r www wwwwwwwwwmomum non

wwwwwwwwwwwwwwww . wwwww

ople 50MICRONS. 60MICRONS. 70MICRONS FIG.11B

khan www eb w the in are we w w w w w What vw ki SUR ------ASS WAS N w Dead Hens W h o we WAN couco : ex n . io. W sieww ws W . W :

58866 2006 m . de er s 9 R SYKES : See xsto www www sexce was when we w

70MICRONS. FIG.11A 40MICRONS 60MICRONSwww.

------se olin selected ------w- - on 1 .

wwi liw e w WON W WAR !440094 Awie www US 2017 /0290768 A1 Oct. 12 , 2017

COMPOSITIONS AND METHODS FOR Joe 's , etc . The target of most products on the market is to SELECTIVE GI TRACT DELIVERY alleviate the morning- after hangover symptoms. With very similar compositions — mainly B + C vitamins, minerals and FIELD AND BACKGROUND OF THE amino acids, these products target the replenishment of the INVENTION body of the depletion of these important compounds during 10001 ] The present invention relates to compositions and excess blood alcohol metabolism . SobrietolTM takes a dif methods of using same for selective delivery of active ferent approach , by incorporating alcohol metabolizing ingredients in the GI tract . Embodiments of the present enzymes , which target the decomposition of the consumed invention relate to a liquid (aqueous ) preparation incorpo alcohol in the stomach and intestines , and thus reduce the rating soluble and / or suspended bioactive ingredients for absorption of alcohol into systemic circulation . Naturally , a remedying the effects of excessive alcohol consumption . person needs to consume Sobrietol prior to alcohol con [0002 ] Alcohol is the most popular legal intoxicant around sumption , in order for the Sobrieto1TM product to demon the globe . The current global market for alcoholic beverages strate some level of efficacy . A third approach is taken by is in excess of $ 900B a year. In Europe , for example , the Party SmartTM . This product incorporates a number of plant average daily consumption of alcohol per person is in excess extracts, which claim targeting the protection of liver dam of 40 grams of pure alcohol. This average daily alcohol age through anti - oxidant activities and through affecting consumption quantity is comparable to the consumption of increased alcohol metabolizing enzymes ' activity . Similar to 3 beers . the other above -mentioned products, Party SmartTM needs to 10003 ] Alcohol consumption intoxicates the human body be consumed prior to alcohol consumption . Human data and results in a wide variety of short term and not infre demonstrating the impact of these products on hangover and quently long term negative side effects and outcomes . The blood alcohol is very limited , or demonstrate very limited first metabolic intermediate generated through alcohol efficacy. metabolism in the human body is acetaldehyde, a toxic [0006 ] Therefore , there remains a need for a composition compound even at very low concentrations . Therefore , in of- matter that can be used to remedy the negative effects of order to avoid irreversible short term health damages and excess alcohol consumption . optionally death , the rate of alcohol metabolism by the human body is limited by its ability to metabolize and SUMMARY OF THE INVENTION remove blood and/ or cell -attached and / or tissue -attached acetaldehyde . As a result , the rate of blood alcohol metabo [ 0007 ] According to one aspect of the present invention lism is quite slow , typically ranging between 0 .03 - 0 .15 gram there is provided a composition -of - matter comprising at percent per hour by occasional alcohol consumers, and up to least two types of microparticles each formed from an active 0 . 15 -0 .25 gram percent per hour by binge and alcoholic ingredient core encapsulated by at least one coating material, drinkers . the at least two types of said microparticles being differen [ 0004 ] Alcohol significantly impairs both motor and cog tiated by the active ingredient or the at least one coating nitive performance. The most critical activity impaired by material . blood alcohol and blood acetaldehyde is driving , which is [0008 ]. According to further features in preferred embodi materially negatively affected by the effect of alcohol and ments of the invention described below each of the at least acetaldehyde on the brain , resulting in reduced cognitive and two types of said microparticles is capable of releasing the motor performance , and further accompanied by the impair active ingredient at a different region of a GI tract . ment of judgment and sliding into reckless behavior and [0009 ] According to still further features in the described undesired risk taking. Yet , only lately , a series of clinical preferred embodiments the microparticles have a diameter research studies found out, that while motor function fol of 25 -100 microns . lowing alcohol consumption is more quickly restored when [0010 ] According to still further features in the described BAC level is on the decreasing slope , cognitive performance preferred embodiments the active ingredient core of the and maintenance of reckless behavior/ risk taking signifi composition -of -matter comprises at least one of: ( a ) dietary cantly lags behind it. This means, that the alcohol intoxi supplements having cognitive and motor function ; ( b ) cated individual subjectively feels recovered from the dietary supplements having anti - gastroparesis , antiemetic , intoxicating effects of excess alcohol consumption , where in analgesic and anti - inflammatory activities ; and / or ( c ) dietary reality, the impaired cognitive judgment and response func supplements being capable of increasing alcohol catabolism . tions are still far from normal . This phenomena is true in [ 0011 ] According to still further features in the described many cases where the blood alcohol levels are already preferred embodiments the composition -of -matter com within legal limits in many countries around the globe . This gap between motor performance recovery and cognitive prises (a ) and (b ), (b ) and (c ) or (a ) and (c ). (and judgment) performance recovery is a major reason why [0012 ] According to still further features in the described cognitive function ' impaired drinkers make a decision to preferred embodiments at least some of the dietary supple enter their car and drive , leading - in an ineligible number of ments of ( a ) - ( c ) are encapsulated within microparticles. events - to severe and not infrequently - lethal accidents . [0013 ] According to still further features in the described 10005 ] Several products in the market attempt to resolve preferred embodiments the composition - of- matter is formu some of the negative outcomes of excess alcohol consump lated as a beverage . tion . These products are frequently powder - based products , [0014 ] According to still further features in the described which need to be reconstructed into liquid (typically water ) preferred embodiments the composition - of- matter is formu prior to its consumption . Examples of such products are lated as a gel. According to still further features in the Sobrieto1TM , Party SmartTM , Drinkin ' MateTM , NOHOTM , described preferred embodiments a pH of the beverage or RU - 21TM , Hangover HaterTM , AL -neutralizerTM , Hangover the gel is 2 . 4 - 3 . 5 . US 2017 /0290768 A1 Oct. 12 , 2017

[0015 ] According to still further features in the described group consisting of Bilobalide, Ginkgolide B , Quercetin , preferred embodiments , the beverage or gel do not contain Gingerols , Shogaols , Parthenolides , Proanthocyanidins and enzymes . Menthol . [0016 ] According to further features in the described [ 0027 ] According to still further features in the described embodiments , the dietary supplements having cognitive and preferred embodiments the dietary supplement having ago motor function are selected from the group having antago nistic activity against Glutamate is selected from the group nistic activity against GABA , Adenosine A1, AchE , Dop consisting of Bilobalide , Huperzine A , N - Acetyl- Cysteine , amine D1, Dopamine D2, Dopamine D3 , 5 -HT1A , 5 -HT2 Acetyl- L -Carnitine , Glutamic acid , Glycine , L -Glutamate , and 5HT3 ; and ; agonistic activity against Glutamate , L - aspartate , L - Alanine , Magnesium and Zinc. Adenosine A2A , 5 -HT1B and 5 -HT4 [0028 ] According to still further features in the described [0017 ] According to still further features in the described preferred embodiments the dietary supplement having ago preferred embodiments the dietary supplement having nistic activity against Adenosine A2A is selected from the antagonistic activity against GABA is selected from the group consisting of Polygala Limonene , Tenuifolia , Acorns group consisting of Bilobalide , Ginkgolides ( A , B & C ) , gramineus, and Poria cocos . Puerarin , Resveratrol, Quercetin , Curcumin , Caffeine , The [0029 ] According to still further features in the described ophylline , Amentoflavone , Dihydromyricetin and Copper preferred embodiments the dietary supplement having ago Glycinate Chelate. nistic activity against 5 -HT1B is selected from the group [0018 ] According to still further features in the described consisting of Limonene, Gingerols , Shogaols, Sulforaphane , preferred embodiments the dietary supplement having Betaine and N - Acetyl -Cysteine . [0030 ] According to still further features in the described antagonistic activity against Adenosine Al is selected from preferred embodiments the dietary supplement having ago the group consisting of Caffeine and Theophylline . nistic activity against 5 -HT4 is selected from the group [0019 ] According to still further features in the described consisting of Mangiferin . preferred embodiments the dietary supplement having [0031 ] According to further features in the described antagonistic activity against AchE is selected from the group embodiments , the dietary supplements having anti - gastro consisting of Huperzine A and Rosmarinic acid . paresis , antiemetic , analgesic and anti - inflammatory activi [0020 ] According to still further features in the described ties are selected from the group having antagonistic activity preferred embodiments the dietary supplement having against Dopamine Di , Dopamine D2 , Dopamine D3 , antagonistic activity against Dopamine D1 is selected from 5 -HT3 ; and ; agonistic activity against CB1 , CB2 , TRPA1 , the group consisting of Ginkgolide A , Parthenolides , Salicin , TRPV1, 5 -HT4 , and ; further activity providing COX inhi Eriodictyol, N - Acetyl -Cysteine , Magnesium , Zinc, Amen bition / suppression , Prostaglandin synthesis suppression , toflavone , Adiantum venestum , Amaranthus virdis , Hout Histamine inhibition , AMPK upregulation and vascular tuynia cordata , Minthostachys mollis , Sargassum fusiforme spasm reduction . and Usnea florida. [0032 ] According to still further features in the described [0021 ] According to still further features in the described preferred embodiments the dietary supplement having ago preferred embodiments the dietary supplement having nistic activity against CB1 and /or CB2 is selected from the antagonistic activity against Dopamine D2 is selected from group consisting of Cannabidiol and Falcarinol, the group consisting of Limonene, Parthenolides, Eriodic 10033 ] According to still further features in the described tyol, N -Acetyl -Cysteine , Alpha Lipoic Acid , Magnesium , preferred embodiments the dietary supplement having ago Zinc , Amentoflavone , Adiantum venestum , nistic activity against TRPA1 is selected from the group [0022 ] Amaranthus virdis , Houttuynia cordata , Minthos consisting of Shogaols , Zinc, Mustard oil and Carnosol. [0034 ] According to still further features in the described tachys mollis , Sargassum fusiforme and Usnea florida??? preferred embodiments the dietary supplement having ago [0023 ] According to still further features in the described nistic activity against TRPV1 is selected from the group preferred embodiments the dietary supplement having consisting of Shogaols , Piperin , Magnesium , Omega - 3 , antagonistic activity against Dopamine D3 is selected from Achinacea , Carvone and Camphor. the group consisting of Ginkgolide C , Parthenolides, Erio [0035 ] According to still further features in the described dictyol, N - Acetyl -Cysteine , Magnesium , Zinc, Amentofla preferred embodiments the dietary supplement having Cox vone , Adiantum venestum , Amaranthus virdis , Houttuynia inhibitor activity is selected from the group consisting of cordata , Minthostachys mollis , Sargassum fusiforme and Curcumin , Thunder God Vine, Resveratrol, Quercetin , Usnea florida . Kaempferol, Pycogenol, Parthenolides , EGCG , Ursolic [0024 ] According to still further features in the described acid , Berberine and Ginsenosides. preferred embodiments the dietary supplement having [0036 ] According to still further features in the described antagonistic activity against 5 -HT1A is selected from the preferred embodiments the dietary supplement having Pros group consisting of Limonene, Proanthocyanidins and Zinc . taglandin inhibitor activity is selected from the group con [0025 ] According to still further features in the described sisting of Gingerols , Shogaols , Salicin and Hesperidin . preferred embodiments the dietary supplement having [0037 ] According to still further features in the described antagonistic activity against 5 -HT2 is selected from the preferred embodiments the dietary supplement having His group consisting of Puerarin , Limonene , Quercetin , Parthe tamine inhibitor activity is selected from the group consist nolides, Salicin , Sulforaphane , Proanthocyanidins and Men ing of Quercetin , Vitamin C , Mangosteen , and Butterbur. thol. [0038 ] According to further features in the described [0026 ] According to still further features in the described embodiments , the dietary supplements capable of increasing preferred embodiments the dietary supplement having alcohol catabolism are selected from the group consisting of antagonistic activity against 5 -HT3 is selected from the alcohol and acetaldehyde catabolism co -factors , acetate US 2017 /0290768 A1 Oct. 12 , 2017

catabolism co - factors , an upregulator of ADH activity , an enable mixing of the composition - of- matter with the liquid upregulator of ALDH activity , an upregulator of Cyp2E1 to generate a consumable suspension . activity , an upregulator of NAD + activity , an acetaldehyde [0051 ] According to still further features in the described binding agent, an upregulator or activator of AMPK and / or preferred embodiments the composition -of - matter includes SIRT; and a down - regulator of CD38 , CD157 and/ or PARP. Bilobalide, Dihydromyricetin (Ampelosin ) Ginkgolides , [0039 ] According to still further features in the described Puerarin , Limonene, Huperzine , Gingerols , Shogaols , Sali preferred embodiments the dietary supplement is an Alcohol cinic acid , Parthenolides , Proanthocyanidins , Curcumin , and / or Acetaldehyde catabolism co - factor selected from the Piperin , Quercetin , Sesamin , Mangiferin , Co - Enzyme A group consisting of B Vitamins: 1 , 2 , 3 , 5 ,6 , 9 and 12 , Pan and /or Amentoflavone , tethine , Vitamin E , TMG (Betaine ), Choline salt , Zinc salt , [ 0052 ] According to still further features in the described SAMe, Nicotinamide , Folate /Folic acid and Alpha Lipoic preferred embodiments the Bilobalide, Dihydromyricetin Acid . ( Ampelosin ) Ginkgolides, Puerarin , Limonene, Huperzine , [0040 ] According to still further features in the described Gingerols , Shogaols , Salicin /Salicinic acid , Parthenolides , preferred embodiments the dietary supplement is an Acetate Proanthocyanidins, Curcumin , Piperin , Quercetin , Sesamin , catabolism co - factor such as Co - enzyme A . Mangiferin , Co- Enzyme A and / or Amentoflavone , are [0041 ] According to still further features in the described microencapsulated . preferred embodiments the dietary supplement is an Acet 10053 ] According to still further features in the described aldehyde binding agent selected from the group consisting preferred embodiments the microparticles include an encap of Proanthocyanidins and Cysteinylglycine. sulant not soluble in acidic , enzyme- free liquid such as Zein [0042 ] According to still further features in the described and Shellac . preferred embodiments the dietary supplement is an upregu 0054 ] According to still further features in the described lator of ADH activity selected from the group consisting of preferred embodiments the microparticles further include Magnesium and Zinc . Shellac , HPMC , glycerol and /or talcum . [0043 ] According to still further features in the described [0055 ) According to still further features in the described preferred embodiments the dietary supplement is an upregu preferred embodiments the microparticles include Shellac , lator of ALDH activity selected from the group consisting of and at least one compound selected from the group consist Sulforaphane , N - Acetyl- Cysteine and Alpha Lipoic Acid . ing of HPMC , HPMCP, Zein , PVA , Carbomer 940 , Methyl [0044 ] According to still further features in the described Cellulose , Ethyl Cellulose, Alginate , Whey , Casein , a plas preferred embodiments the dietary supplement is an upregu ticizer, ( such as PEG , Triethyl Citrate and Glycerol ) and lator of NAD + activity selected from the group consisting of Talc . Resveratrol, Quercetin , Caffeine , Theophylline , Betaine! [ 0056 ] According to still further features in the described TMG , Choline , N - Acetyl- Cysteine, Alpha Lipoic Acid , preferred embodiments the microparticles include one or a Acetyl- L - Carnitine , Pyruvate , Co -Enzyme A and Fructose . combination of Prolamin proteins (Zein , Wheat, etc . ) , Shel [0045 ] According to still further features in the described lac , fats ( Coconut oil , Palm oil ) , Gelatin , Soy proteins , Pea preferred embodiments the dietary supplement is an upregu proteins (Globulin ) , Vegetable proteins , Dextran , Maltodex lator of AMPK activity selected from the group consisting of trin , Cyclodextrin , Whey , Caseine , Guar gum , gum Arabic , Bilobalide , Puerarin , Resveratrol, Quercetin , Shogaols , Sali Pectin , Amylose, Starches, Guar gum , Pectins , Chitosans , cin , Sulforaphane , Menthol, Betaine / TMG , Choline , Alpha Alginates , Hydrogels , Polymethacrylates , Ethyl Cellulose , Lipoic Acid and Acetyl- L - Carnitine . Methyl Cellulose . [ 0046 ] According to still further features in the described [0057 ] The present invention successfully addresses the preferred embodiments the dietary supplement is an upregu shortcomings of the presently known configurations by lator of SIRT activity selected from the group consisting of providing a composition - of -matter that can be used to Resveratrol, Quercetin , Curcumin , Sulforaphane , N -Acetyl reduce or reverse both the physiological, motor and cogni Cysteine and Fructose . tive effects of alcohol on the body and / or deliver active 10047 ] According to still further features in the described ingredients to various regions of the GI in a timely manner. preferred embodiments the dietary supplement is a down [0058 ]. Unless otherwise defined , all technical and scien regulator of CD38 and / or CD157 activity selected from the tific termsused herein have the same meaning as commonly group consisting of Quercetin . understood by one of ordinary skill in the art to which this 10048 ) According to still further features in the described invention belongs. Although methods and materials similar preferred embodiments the dietary supplement is a down or equivalent to those described herein can be used in the regulator of PARP activity selected from the group consist practice or testing of the present invention , suitable methods ing of Quercetin , Caffeine , Theophylline , Curcumin , Sul and materials are described below . In case of conflict, the foraphane , Eriodictyol, Betaine / TMG , N - Acetyl- Cysteine patent specification , including definitions , will control. In and Pyruvate . addition , the materials , methods, and examples are illustra [ 0049 ] According to another aspect of the present inven tive only and not intended to be limiting. tion there is provided an article ofmanufacturing comprising a container having two environmentally isolated compart BRIEF DESCRIPTION OF THE DRAWINGS ments , a first compartment including the composition - of [0059 ] The invention is herein described , by way of matter of claim 1 and , a second compartment including a example only , with reference to the accompanying drawings . liquid , wherein at least a portion of the dietary supplements With specific reference now to the drawings in detail , it is of ( a ) , ( b ) and / or ( c ) are encapsulated within microparticles stressed that the particulars shown are by way of example having a diameter of 25 - 100 microns . and for purposes of illustrative discussion of the preferred 10050 ] According to still further features in the described embodiments of the present invention only , and are pre preferred embodiments the container is constructed so as to sented in the cause of providing what is believed to be the US 2017 /0290768 A1 Oct. 12 , 2017 most useful and readily understood description of the prin [0074 ] ( ii ) due to solubility and bad taste issues, such ciples and conceptual aspects of the invention . In this regard , products incorporate relatively small quantities ( w / v or v / v ) no attempt is made to show structural details of the invention of active ingredients , such small quantities are not effective in more detail than is necessary for a fundamental under - in timely coping with the dozens of milliliters of circulating standing of the invention , the description taken with the pure alcohol and its metabolites . drawings making apparent to those skilled in the art how the [0075 ] ( iii ) compounds (vitamins , minerals , amino acids , several forms of the invention may be embodied in practice . etc . ) depleted in the body during alcohol metabolism are [0060 ] In the drawings: water soluble (hydrophilic ) and water insoluble (hydropho [ 0061] FIG . 1 illustrates a container suitable for delivery bic ). Thus, replenishment of such compounds requires that of the present composition . both types of ingredients are present in a single liquid [ 0062] FIG . 2 illustrates non - encapsulated Glucose (left medium (for ensuring very quick availability in the GI tract) . image ) and Shellac -based encapsulated Glucose ( right This results in a less than favorable consumption experience image ). since some of the ingredients are present as a bad - tasting [0063 ] FIGS . 3 -6 illustrate the effect of the present com suspension ; position on the motor and cognitive functions of an intoxi [0076 ] ( iv ) some of the key compounds depleted from the cated subject. body during alcohol metabolism are poorly absorbed [0064 ] FIG . 7 is a graph showing release of Vitamin B2 in through the intestines . As such , very little quantities of such an aqueous medium having a pH of 1 . 1 . ingredients are naturally absorbed into the blood stream [0065 ] FIGS. 8a - b schematically illustrate one embodi from presently available products; ment of a two microparticle powder of the present invention [0077 ] (v ) some ingredients suitable for use in such prod showing the active ingredient core surrounded by one or ucts have an unpleasant taste and as such are often not used ; more coating layers of each particle type . [0078 ] ( vi ) existing products do not address the negative [ 0066 ] FIGS . 9a - c schematically illustrate one embodi effects of alcohol and its metabolites on cognitive functions ment of a three microparticle powder of the present inven such as information processing , memory , attention , concen tion showing the active ingredient core surrounded by one or tration , decision making / impulse control, risk taking, and / or more coating layers of each particle type. motor functions ; [ 0067 ] FIGS. 10a - ch schematically illustrate another 10079 ] (vii ) limited human data publically available for embodiment of a three microparticle powder of the present existing products demonstrates an alcohol metabolism invention showing the active ingredient core surrounded by acceleration of 5 % - 15 % . This is relatively a low and insuf one or more coating layers of each particle type . ficient acceleration outcome from a consumer standpoint . [0068 ] FIGS. 11a -c schematically illustrate another [0080 ] (viii ) existing products do not address the gastro embodiment of a three microparticle powder of the present paresis effects of alcohol consumption , which prevent or at invention showing the active ingredient core surrounded by the minimum significantly slow - down the passage of replen one or more coating layers of each particle type . ishing ingredients past the stomach and its absorption start ing in the Duodenum . DESCRIPTION OF THE PREFERRED 10081 ] ( ix ) Existing products do not address , sufficiently EMBODIMENTS early , the negative physiological sensations resulting from alcohol consumption ( e . g . nausea / vomiting, headache /mi [0069 ] The present invention is of a composition -of - mat graine , stomach pain / abdominal pain , fatigue , etc . ) . As a ter which can be used to selectively deliver ingredients in the result , instead of preventing the initiation of these symp GI tract for the purpose of, for example , but not limited to , toms, existing products target the reduction of symptoms rapidly reversing or reducing the negative effects of alcohol after they have already occurred (typically the morning consumption . after ). [0070 ] The principles and operation of the present inven [0082 ] ( x ) technologies for minimizing unpleasant taste tion may be better understood with reference to the drawings primarily focus on taste masking . Taste masking can be and accompanying descriptions and examples . effective in protection against a few hundred milligrams (at [0071 ] Before explaining at least one embodiment of the most ) of bad tasting ingredients in a beverage or gel, but are invention in detail , it is to be understood that the invention ineffective when attempting to mask the bad tastes of is not limited in its application to the details set forth in the ingredients at higher quantities . following description or exemplified by the Examples . The [0083 ] While reducing the present invention to practice , invention is capable of other embodiments or of being the present inventors formulated a composition -of - matter practiced or carried out in various ways . Also , it is to be that can be used to rapidly and timely remedy the variety of understood that the phraseology and terminology employed negative effects of alcohol consumption while addressing herein is for the purpose of description and should not be the above limitations of prior art products . regarded as limiting . [0084 ] The present composition provides the following [0072 ] Several products attempt to provide relief from , or advantages : reduce the negative effects of alcohol consumption . Such [0085 ] ( a ) it can accelerate alcoholmetabolism in the body products are unpopular with drinkers and do not provide the by as much as 100 % ; benefits claimed at least for the following reasons: [0086 ] (b ) it can effectively reduce the effect of alcohol on [ 0073] (i ) people drink alcohol to enjoy its actual and /or the brain , specifically the negative effects of alcohol on perceived positive impacts : improved mood , social open information processing, memory , cognition , decision mak ness , etc . A product which is consumed prior to and / or ing/ impulse control, risk taking and motor performance ; concurrently with alcohol consumption , can reduce the [ 0087 ] ( c ) it can reduce the effect of alcohol on the body , desired effects of alcohol sought by drinkers. specifically the negative effects of alcohol on physiology US 2017 /0290768 A1 Oct. 12 , 2017

( e. g . nausea , vomiting, fatigue, headache , migraine , light Carbohydrates which are typically used as an energy source , headedness , stomach pain , abdominal pain , etc .) ; can also affect alcohol catabolism and are also optionally 10088 ] ( d ) it can be consumed anytime following alcohol used in the present composition . consumption while not negatively affecting the desired [0103 ] Although any of the above ( a )- ( c ) can individually effect of alcohol as perceived by the consumer ; provide a beneficial effect on individuals under alcohol 10089 ] ( e ) it can provide effective quantities of the active influence or intoxicated individuals , it will be appreciated ingredients in a relatively small volume of liquid , having a that a composition -of -matter that includes ( a ) and ( b ) , ( a ) positive effect on the rate of response and effectiveness; and (c ), ( b ) and (c ) or ( a )- (c ) is preferred due to its combined [0090 ] (f ) it does not have an unpleasant taste or odor, effects. even when the amount of ingredients is significant (between [0104 ] Examples of dietary supplements of ( a ), ( b ) or ( c ) 10 - 100 grams) ; are described hereinbelow . A composition of matter that [0091 ] ( g ) it can improve some of the negative effects of includes dietary supplements encompassing ( a ) , ( b ) and ( c ) alcohol as early as 5 - 10 minutes post the beginning of is exemplified by Table 8 . consumption ; [0105 ] According to another aspect of the present inven [0092 ] ( h ) it can prolong the duration of significant pre - tion there is provided a composition -of -matter which vention or improvement of the alcohol intoxication symp includes the following active ingredients : toms to 2 - 8 hours post a single consumption ; [0106 ] ( a ) dietary supplements for reducing or abolishing [0093 ] ( i ) it is effective in treating both low blood alcohol the negative effects of alcohol on cognition , attention , con levels ( e . g . 0 . 020 % - 0 .050 % ) as well as high blood alcohol centration , memory , information processing , decision mak levels (e . g. 0 .050 % -0 .200 % ); ing, risk taking and /or impulse control, for example , supple [0094 ] (j ) It is effective in recovering gastrointestinal ments which exhibit antagonistic activity against GABA , motility temporarily impaired by alcohol consumption ; dopamine , and serotonin and agonistic activity against glu [ 0095 ] ( k ) It is effective in recovering capabilities relating tamine ; to information processing , memory , attention , decision mak [0107 ] (b ) dietary supplements having free - radical scav ing, impulse control, risk taking and motor performance enging , anti - gastroparesis , antiemetic , analgesic and anti impaired by alcohol consumption . inflammatory activities ; and /or 10096 ] An embodiment of the composition - of matter of [0108 ] ( c ) dietary supplements capable of increasing alco the present invention (also referred to herein as “ the present hol catabolism and /or reducing the levels of toxic products composition ” ) was formulated as a consumable liquid prepa resulting from alcohol catabolism . ration and tested on intoxicated individuals . As is described 0109 ]. Although any of the above ( a ) - ( c ) can individually in the Examples section which follows, consumption of the provide a beneficial effect on individuals under alcohol present composition following alcohol consumption led to influence or intoxicated individuals , it will be appreciated recovery of gastrointestinal motility temporarily impaired that a composition - of -matter that includes ( a ) and ( b ) , ( a ) by alcohol consumption , accelerated blood alcohol metabo and ( c ) or ( b ) and ( c ) or ( a ), (b ) and (c ) is presently preferred lism , facilitated quicker recovery of motor, cognitive , infor due to its combined effects . mation processing , memory , concentration , attention , deci [0110 ) A dietary supplement having antagonistic activity sion making, impulse control, risk taking mitigation against GABA can be, for example , Bilobalide , Amentofla capabilities ; and ; improved negative physiological sensa vone, Dihydromyricetin and Copper Glycinate Chelate . tions ( e . g . nausea , vomiting, headache, migraine , stomach These exist in low concentrations in commercially available pain , abdominal pain , tiredness , exhaustion , etc . ) resulting extracts of Ginkgo Biloba and Hovenia Dulcis, and its from excess alcohol consumption . concentrations in extracts can be further elevated using [0097 ] As used herein , excess alcohol consumption refers commercially available extraction and purification technolo to an amount of alcohol that when consumed results in gies . i . e . Bilobalide , Amentoflavone , Dihydromyricetin can negative cognitive and / or physiological effects on the user. be sourced as a powdered extract from Ginkgo Biloba and As used herein , “ alcohol intoxication ” or “ excess alcohol Hovenia Dulcis while Copper Glycinate Chelate can be consumption ” refers to user 's blood alcohol levels greater sourced as a Copper Glycinate Chelate from dietary supple than 0 .05 % . ment manufacturers . [ 0098 ] Thus, according to one aspect of the present inven [0111 ] A dietary supplement having agonistic activity tion there is provided a composition of matter which against glutamate can be , for example , L -Glutamate , L -as includes the following active ingredients : partate , L - Alanine , Magnesium and Zinc. [ 0099 ] ( a ) dietary supplements affecting motor and , cog [0112 ] A dietary supplement having antagonistic activity nitive performance ; against dopamine can be , for example , Amentoflavone , [ 0100 ] (b ) dietary supplements having anti- gastroparesis , Adiantum venestum , Amaranthus virdis , Houttuynia cor antiemetic , analgesic and anti- inflammatory activities ; and / data , Minthostachys mollis , Sargassum fusiforme and Usnea or florida . Amentoflavone is present in different concentrations [0101 ] ( c ) dietary supplements being capable of increasing in Ginkgo Biloba extract. Extracts of Adiantum venestum , alcohol catabolism . Amaranthus virdis , Houttuynia cordata , Minthostachys mol [ 0102 ] As used herein , a dietary supplement refers to a lis, Sargassum fusiforme and Usnea florida are available product taken orally that contains one or more ingredients from herbal extract manufacturers , primarily in China , India that are intended to supplement an individual' s diet and is and South America . not considered food ( i. e . are not typically an energy source ) . [0113 ] A dietary supplement having antagonistic activity Dietary supplements can be vitamins , minerals , herbs or against serotonin can be, for example , Bilobalide, Gink other botanicals or extracts thereof, amino acids , or any golides , Gingerols , Ginsenosides, Amentoflavone and Puer other non -food substances capable of supplementing a diet. arin . Bilobalide, Amentoflavone and Ginkgolides are present US 2017 /0290768 A1 Oct. 12 , 2017 in different concentrations in extracts of Ginkgo Biloba . active ingredients . Such microcapsules also enable loading Gingerols are present in different concentrations in extracts of an effective amount of active ingredients in a liquid unit from Ginger , Ginsenosides are present in different concen of several hundreds of milliliters, or in a gel . As is further trations in extracts from differ varieties of Ginseng . Puerarin described in the Examples section which follows, microen is present in different concentrations in extracts from Puer capsulation was also selected so as to minimize or negate the aria Lobata (Kudzu ) . gritty oral sensation often accompanied with consumption of 10114 ) Dietary supplements that can increase alcohol suspended powders . Such gritty oral sensation of a beverage breakdown in the body or that reduce the level of toxic or a gel is a major obstacle to obtain a satisfactory positive products of catabolism include , for example , an upregulator consumption experience by the user . of ADH activity , upregulator of ALDH1 activity , an upregu (0123 ] In addition , the present microencapsulation lator of ALDH2 activity , an upregulator of Cyp2E1 activity, approaches were designed in order to selectively release an upregulator of NAD + activity , an acetaldehyde binding different active ingredients ( e . g . dietary supplements ) agent and an upregulator or activator ofAMPK and /or SIRT. throughout the GI tract ( see the Examples section which [0115 ] A dietary supplement capable of increasing alcohol follows for further description ). catabolism can be , for example , a B Vitamin ( e .g . Vitamin [0124 ] Several types of micro - encapsulation approaches B1 , 2 , 3 , 5 , 6 , 9 and /or 12 ), Pantethine, Vitamin E , TMG can be used to encapsulate the dietary supplements of the ( Betaine ), Choline salt, Zinc salt , SAMe, Nicotinamide , present composition . Examples of such approaches include Folate /Folic acid and Alpha Lipoic Acid . encapsulating the dietary supplement raw materials with [ 0116 ] Vitamin B6 , Vitamin B12 and Folate can also be enteric and / or other encapsulating materials in a fluidized used as a Methionine metabolism recovery agent. Such an bed ; spray - drying a mixture of a dietary supplement and agent can reduce liver injury and circulating Homocysteine enteric / encapsulant ingredients ; and / or , freeze - drying a mix levels . ture spray -drying a mixture of a dietary supplement and [0117 ] An example of an acetaldehyde binding agent can enteric / encapsulant ingredients , and then grinding it to the be Proanthocyanidins or Cysteinylglycine, while an upregu desired final particle size / diameter. lator or activator of AMPK and / or SIRT can be Resveratrol, [0125 ] The Examples section which follows describes Sulforaphane , Fructose and Curcumin . These ingredients several approaches for encapsulating the dietary supple can be sourced from grapes , Broccoli and Curcuma Longa ments of the present composition . The advantages of the from dietary supplement and plant extract manufacturers technological approach is that given optimal parameters , it around the globe. enables the generation of an effective isolative coating even 0118 ]. As is described hereinabove , the present composi in cases of very small particles of dietary supplements which tion can also include a dietary supplement having anti are characterized by a foul taste and / or odor. gastroparesis, antiemetic , analgesic and / or anti- inflamma [0126 ] Dietary supplements which are preferably encap tory activities . sulated include, but are not limited to , Alpha Lipoic Acid , [0119 ] An example of an antiemetic agent acting as a Folic acid , Vitamin B1, Vitamin B2 , Vitamin B3 (Nicoti serotonin ( 5 -HT ) antagonist which can be used in the present namide ), Vitamin B5/ Pantethine , Vitamin B6 , Vitamin B9 composition is Proanthocyanidins , Gingerols , Ginsenosides, ( Folate ), Vitamin Bilobalide or Ginkgolides , an anti -Gatroparesis agent acting [0127 ] B12, Vitamin D , Vitamin E , Glutathione , Carnitine/ as TRPV1 agonist and / or TRPA1 agonist can be Eriodictyol, Acetyl- L -Carnitine , Cysteine / N -Acetyl -Cysteine , Copper Ursolic Acid , Capsaicin , alpha -Spinasterol , Gingerols , salt, Selenium salt , Magnesium salt , Zinc salt , Pyruvate salt , Shogaols, MSG and Kiwi extract . Eriodictyol is present in a Co - enzyme A , Curcumin , Piperin , Quercetin , Resveratrol, variety of concentrations in extracts of Yerba Santa . Cap Sesamin , Sulforaphane , Astaxanthin , Lemon (Limonene ) , saicin is present in a variety of concentrations in extracts of Grape seed (Proanthocyanidins ) , Huperzia (Huperzine ) , Peppers . Ursolic acid is present in a variety of different Pueraria Lobata (Puerarin ) , Ginseng (Ginsenosides ) , Ginkgo concentrations in extracts of Berries and Basil. Gingerols are Biloba present in a variety of concentrations in extracts of Ginger. 10128 ] ( Bilobalide , Amentoflavone , Ginkgolides ) , Alpha - Spinasterol is present in a variety of concentrations in Guarana ( Caffeine , Theophylline ) , Ginger (Gingerols , extracts of Spinach . MSG is available from a variety of food Shogalos ), Feverfew (Parthenolides ), White Willow Bark additive manufacturers . ( Salicylic acid ), Mango (Mangiferin ) , Betaine ( TMG ) , [0120 ] The present composition can also include a lipid SAMe, Choline salt , Creatine , Fructose and Glucose . metabolism upregulating agent such as Creatine , Carnitine [0129 ] Tables 1 - 14 below provide several exemplary com and Acetyl- L - Carnitine, as well as fish oil . positions formulated according to the teachings of the pres [0121 ] As is mentioned hereinabove, formulating a prod ent invention . uct capable of effectively reducing the variety of negative effects of excess alcohol consumption ( also referred to TABLE 1 herein as an “ alcohol recovery product” ) is challenging due Total (mg . ) Total (mg . ) to two main problems: providing a functionally - effective Dietary Supplement Low High amount of the active ingredients in a consumable product Alpha Lipoic Acid 300 600 unit to facilitate a rapid and significant physiological effect, Folic acid 2 . 4 3 . 2 and, formulating the product such that the flavor and odor Vitamin B1 500 500 thereof are not unpleasant to the user. Vitamin B2 200 200 Vitamin B3 (Nicotinamide ) 250 750 [0122 ] The present inventors have addressed these issues Pantethine 600 900 by encapsulating some of the ingredients in microcapsules Vitamin B6 200 200 with different coatings which isolate , rather than mask , the Vitamin B12 odors and the flavors of unpleasant tasting and smelling US 2017 /0290768 A1 Oct. 12 , 2017 7

TABLE 1 -continued TABLE 3 - continued Total (mg . ) Total (mg . ) Total (mg . ) Total (mg .) Dietary Supplement Low High Dietary Supplement Low High Acetyl- L - Carnitine 500 1 , 000 Vitamin B1 500 500 N - Acetyl- Cysteine 600 1 , 200 Vitamin B2 200 200 Copper Glycinate Chelate 2 2 Vitamin B3 ( Nicotinamide ) 250 750 Selenium Chelate 200 200 Pantethine 600 900 Magnesium 500 500 Vitamin B6 200 200 Zinc Citrate 50 50 Vitamin B12 5 5 Vitamin E 400 IU 400 IU Acetyl- L - Carnitine 500 1 , 000 Resveratrol 250 500 N -Acetyl - Cysteine 600 1 , 200 Sulphoraphane 35 70 Copper Glycinate Chelate 2 2 Curcumin 600 1 , 800 Selenium Chelate 200 200 Piperin 60 90 Magnesium 500 500 Fructose 20 , 000 40 ,000 Zinc Citrate 50 50 Betaine ( TMG ) 3 ,000 5 ,000 Vitamin E 400 IU 400 IU Choline Bitratrate 1 ,000 2 ,000 Resveratrol 250 500 Creatine 1 ,000 2 ,000 Sulphoraphane 35 70 American Ginseng (Ginsenosides ) 300 900 Curcumin 600 1 ,800 Ginkgo Biloba (Bilobalide , Ginkgolide B ) 300 600 Piperin 60 90 Hovenia Dulcis ( Dihydromyricetin ) 250 1 , 000 Fructose 20 ,000 40 ,000 Pueraria Lobata (Puerarin ) 600 3 , 000 Betaine ( TMG ) 3 ,000 5 , 000 Guarana extract 600 1 ,200 Choline Bitratrate 1 ,000 2 , 000 Glucose 10 ,000 20 ,000 Creatine 1 ,000 2 , 000 Astaxanthin 20 60 Astaxanthin 20 60 Eriodictyol 150 250 Eriodictyol 150 250 Ginger extract (Gingerols , Shogaols ) 600 2 , 000 Ginger extract (Gingerols , Shogaols ) 600 2 ,000 Feverfew (Parathenolides ) 100 200 Feverfew (Parathenolides ) 100 200 White Willow Bark (Salicylic acid ) 120 240 White Willow Bark ( Salicylic acid ) 120 240

TABLE 2 TABLE 4 Total (mg . ) Total (mg . ) Total (mg . ) Total (mg . ) Dietary Supplement Low High Dietary Supplement Low High Alpha Lipoic Acid 300 600 Curcumin 600 1 , 800 Folic acid 2 . 4 3 . 2 Resveratrol 250 500 Vitamin B1 500 500 Piperin 60 90 Vitamin B2 200 200 American Ginseng (Ginsenosides ) 300 900 Vitamin B3 (Nicotinamide ) 250 750 Ginkgo Biloba ( Bilobalide, Ginkgolide B ) 300 600 Pantethine 600 900 Hovenia Dulcis ( Dihydromyricetin ) 250 1 ,000 Vitamin B6 200 200 Pueraria Lobata (Puerarin ) 600 3 ,000 Vitamin B12 5 5 Guarana extract 600 1 ,200 Acetyl- L - Carnitine 500 1 ,000 Glocose 10 , 000 20 ,000 N - Acetyl -Cysteine 600 1 , 200 Astaxanthin 20 60 Copper Glycinate Chelate 2 Eriodictyol 150 250 Selenium Chelate 200 200 Ginger extract (Gingerols , Shogaols ) 600 2 , 000 Magnesium 500 500 Feverfew (Parathenolides ) 100 200 Zinc Citrate *22839433298950 50 White Willow Bark (Salicylic acid ) 120 240 Vitamin E 400 IU 400 IU Resveratrol 250 500 Sulphoraphane 35 70 Curcumin 600 1 ,800 TABLE 5 Piperin 60 90 Fructose 20 ,000 40 ,000 Total (mg . ) Total (mg . ) Betaine ( TMG ) 3 ,000 5 ,000 Dietary Supplement High Choline Bitratrate 1 , 000 2 ,000 Low Creatine 1 , 000 2 ,000 Alpha Lipoic Acid 300 600 American Ginseng (Ginsenosides ) 300 900 Folic acid 2 . 4 3 . 2 Ginkgo Biloba (Bilobalide , Ginkgolide B ) 300 600 Vitamin B1 500 500 Hovenia Dulcis (Dihydromyricetin ) 250 1 , 000 Vitamin B2 200 200 Pueraria Lobata (Puerarin ) 600 3 , 000 Vitamin B3 ( Nicotinamide ) 250 750 Guarana extract 600 1 , 200 Pantethine 600 900 Glucose 10 , 000 20 ,000 Vitamin B6 200 200 Vitamin B12 5 5 Acetyl- L - Carnitine 500 1 , 000 N - Acetyl -Cysteine 600 1 , 200 TABLE 3 Copper Glycinate Chelate 2 2 Selenium Chelate 200 200 Total (mg . ) Total (mg . ) Magnesium 500 500 Dietary Supplement Low High Zinc Citrate 50 50 Vitamin E 400 IU 400 IU Alpha Lipoic Acid 300 600 Resveratrol 250 500 Folic acid 2 . 4 . 33 . 2 Sulphoraphane 35 70 US 2017 /0290768 A1 Oct. 12 , 2017

TABLE 5 - continued TABLE 8 - continued Total (mg . ) Total (mg . ) Total (mg . ) Total (mg . ) Dietary Supplement Low High Dietary Supplement Low High Curcumin 600 1 , 800 Lemon extract ( Limonene ) 500 1 , 500 Piperin 60 90 Huperzia extract (Huperzine ) 0 . 1 0 . 3 Fructose 20 ,000 40 , 000 Feverfew (Parthenolides ) 100 200 Betaine ( TMG ) 3 ,000 5 ,000 White Willow Bark ( Salicylic acid ) 120 240 Choline Bitratrate 1 ,000 2 ,000 Grape seed extract (Proanthocyanidins ) 250 1 ,000 Creatine 1 ,000 2 ,000 Mango extract ( Mangiferin ) 100 500

TABLE 6 TABLE 9 Total (mg . ) Total (mg .) Total (mg . ) Total (mg . ) Dietary Supplement Low High Dietary Supplement Low High Curcumin 600 1 ,800 Alpha Lipoic Acid 300 600 Resveratrol 250 500 Vitamin B1 500 500 Piperin 60 90 Vitamin B2 200 200 American Ginseng (Ginsenosides ) 300 900 Vitamin B3 ( Nicotinamide ) 250 750 Ginkgo Biloba (Bilobalide , Ginkgolide B ) 300 600 Vitamin B5 ( Pantethine ) 600 900 Hovenia Dulcis ( Dihydromyricetin ) 250 1 ,000 Vitamin B6 200 200 Pueraria Lobata (Puerarin ) 600 3 ,000 Vitamin B9 ( Folate ) 2 . 4 3 . 2 Guarana extract 600 1 , 200 Vitamin B12 Glocose 10 ,000 20 ,000 N -Acetyl - Cysteine 600 1 , 200 Magnesium oxide 500 500 Zinc Citrate 50 50 Vitamin D 400 IU 400 IU TABLE 7 Vitamin E 400 IU 400 IU Calcium Pyruvate 2 ,000 10 ,000 Total (mg . ) Total (mg . ) Betaine ( TMG ) 3 ,000 5 ,000 Dietary Supplement Low High Choline Bitratrate 1 , 000 2 ,000 Co - Enzyme A 500 4 ,000 Curcumin 600 1 ,800 Glutathione 500 2 ,000 Resveratrol 250 500 Glucose 10 ,000 20 ,000 Piperin 60 90 Quercetin 500 1 , 500 Astaxanthin 20 60 Curcumin 600 1 ,800 Eriodictyol 150 250 Piperin 60 90 Ginger extract (Gingerols , Shogaols ) 600 2 ,000 Korean Ginseng (Ginsenosides ) 300 900 Feverfew ( Parathenolides ) 100 200 Ginkgo Biloba (Bilobalide , Ginkgolides ) 300 600 White Willow Bark (Salicylic acid ) 120 240 Pueraria Lobata (Puerarin ) 600 3 ,000 Ginger extract (Gingerols , Shogaols ) 600 2 ,000 Lemon extract ( Limonene ) 500 1 ,500 Huperzia extract (Huperzine ) 0. 1 0 . 3 TABLE 8 Total (mg . ) Total (mg .) Dietary Supplement Low High TABLE 10 Alpha Lipoic Acid 300 600 Total (mg . ) Total (mg . ) Vitamin B1 500 500 Dietary Supplement Low High Vitamin B2 200 200 Vitamin B3 (Nicotinamide ) 250 750 Alpha Lipoic Acid 300 600 Vitamin B5 ( Pantethine ) 600 900 Vitamin B1 500 500 Vitamin B6 200 200 Vitamin B2 200 200 Vitamin B9 (Folate ) 2 . 4 3 . 2 Vitamin B3 ( Nicotinamide ) 250 750 Vitamin B12 Vitamin B5 ( Pantethine ) 600 900 N - Acetyl -Cysteine 600 1 ,200 Vitamin B6 200 200 Magnesium oxide 500 500 Vitamin B9 (Folate ) 2 . 4 3 . 2 Zinc Citrate 50 50 Vitamin B12 5 Vitamin D 400 IU 400 IU N - Acetyl- Cysteine 600 1 , 200 Vitamin E 400 IU 400 IU Magnesium oxide 500 500 Calcium Pyruvate 2 ,000 10 ,000 Zinc Citrate 50 50 Betaine ( TMG ) 3 ,000 5 ,000 Vitamin D 400 IU R400 IU Choline Bitratrate 1 ,000 2 ,000 Vitamin E 400 IU 400 IU Co - Enzyme A 500 4 ,000 Calcium Pyruvate 2 , 000 10 ,000 Glutathione 500 2 ,000 Betaine ( TMG ) 3 ,000 5 ,000 Glucose 10 ,000 20 ,000 Choline Bitratrate 1 ,000 2 ,000 Quercetin 500 1 ,500 Co - Enzyme A 500 4 , 000 Curcumin 600 1 , 800 Glutathione 500 2 , 000 Piperin 60 90 Glucose 10 , 000 20 , 000 Korean Ginseng (Ginsenosides ) 300 900 Quercetin 500 1 ,500 Ginkgo Biloba (Bilobalide , Ginkgolides ) 300 600 Curcumin 600 1 , 800 Pueraria Lobata (Puerarin ) 600 3 ,000 Piperin 60 90 Ginger extract (Gingerols , Shogaols ) 600 2 ,000 Feverfew ( Parthenolides ) 100 200 US 2017 /0290768 A1 Oct. 12 , 2017

TABLE 10 -continued TABLE 14 Total (mg . ) Total (mg . ) Total (mg .) Total (mg . ) Dietary Supplement Low High Dietary Supplement Low High Feverfew (Parthenolides ) 100 200 White Willow Bark ( Salicylic acid ) 120 240 White Willow Bark ( Salicylic acid ) 120 240 Grape seed extract ( Proanthocyanidins) 250 1 ,000 Grape seed extract (Proanthocyanidins ) 250 1 , 000 Mango extract ( Mangiferin ) 100 500 Mango extract ( Mangiferin ) 100 500 [0130 ] The composition -of -matter of the present invention TABLE 11 can be formulated into any consumable product including gels , bars, snacks, shakes or drinks . The composition -of Total (mg . ) Total (mg . ) matter of the present invention is optimized , and thus has Dietary Supplement Low High significant benefits , when delivered in a water - containing Quercetin 500 1 ,500 formulation as a suspension or dispersion . Curcumin 600 1 , 800 [0131 ] Microencapsulation is a technology that is used to Piperin 60 90 protect ingredients from degradation due to heat, moisture Korean Ginseng (Ginsenosides ) 300 900 Ginkgo Biloba (Bilobalide , Ginkgolides ) 300 600 and / or presence of oxygen . Microencapsulation is also used Pueraria Lobata ( Puerarin ) 600 3 ,000 to mask bad odors and tastes of ingredients and to enable Ginger extract (Gingerols , Shogaols ) 600 2 ,000 controlled and targeted release /delivery ofactive ingredients Lemon extract ( Limonene ) 500 1 , 500 in the GI tract. Huperzia extract ( Huperzine ) 0 . 1 0 . 3 Feverfew (Parthenolides ) 100 200 [0132 ] The present invention utilizes microencapsulation White Willow Bark ( Salicylic acid ) 120 240 to isolate the taste and organoleptic characteristic (mouth Grape seed extract (Proanthocyanidins ) 250 1 , 000 sensation of particles ) of various active ingredients and to Mango extract ( Mangiferin ) 100 500 deliver ingredients to different target sites in the GI tract . 0133 ] The microencapsulated active ingredients are for mulated as a powder which can be dispersed in a liquid TABLE 12 beverage , shake or gelprior to consumption . [0134 ] The powder can be manufactured via spray drying Total (mg . ) Total (mg .) with a three fluid or four fluid injectors incorporating more Dietary Supplement Low High than a single fluid nozzle and capable of generating , in a Alpha Lipoic Acid 300 600 single step , a core containing the active ingredient sur Vitamin B1 500 500 Vitamin B2 200 200 rounded by at least one layer of a coating made from , for Vitamin B3 (Nicotinamide ) 250 750 example , cellulose derivatives , proteins, methacrylate and Vitamin B5 (Pantethine ) 600 900 other coating materials known in the food and pharmaceu Vitamin B6 200 200 tical industry . Suitable spray drying technologies for use Vitamin B9 (Folate ) 2 . 4 3. 2 Vitamin B12 5 5 with the present invention include, but not limited to , 3 - fluid N - Acetyl -Cysteine 600 1 , 200 spray drying , 4 - fluid spray drying and ultrasonic dual- fluid Magnesium oxide 500 500 or ultrasonic triple - fluid spray drying . Zinc Citrate 50 50 [0135 ] The final microencapsulated product is a powder Vitamin D 400 IU 400 IU Vitamin E 400 IU 400 IU that is dispersed into , an acidic ( 2 . 0 - 4 . 0 ) liquid beverage , Calcium Pyruvate 2 , 000 10 , 000 shake or a gel. Betaine ( TMG ) 3 ,000 5 ,000 [0136 ] Since the powder is insoluble and includes a high Choline Bitratrate 1 ,000 2 , 000 dose of active ingredients , a particle size optimizing disper Co - Enzyme A 500 4 ,000 Glutathione 500 2 ,000 sion , loading and minimization of a negative mouth sensa Glucose 10 ,000 20 ,000 tion ( organoleptic ) was selected . The present inventors Quercetin 500 1 ,500 uncovered that a particle diameter for optimizing between Curcumin 600 1 , 800 particle loading and positive organoleptic sensation ranges Piperin 60 90 between 20 - 100 microns , with 45 - 75 microns being the preferred size for the aforementioned application . [0137 ] Suspended particles in liquid with a diameter above TABLE 13 100 microns produce an unpleasant sand - like gritty sensa tion in the mouth . Human experiments conducted by the Total (mg . ) Total (mg . ) Dietary Supplement High present inventors uncovered that particles having a diameter Low of 15 to 100 microns do not produce such a sensation . In Quercetin 500 1 ,500 contrast , particles with a diameter of 120 microns or higher, Curcumin 600 1 ,800 Piperin 60 90 typical to the minimum diameter provided by fluidized bed Korean Ginseng (Ginsenosides ) 300 900 coating , generate a very unpleasant gritty , sand - like sensa Ginkgo Biloba (Bilobalide , Ginkgolides ) 300 600 tion in the mouth . Pueraria Lobata (Puerarin ) 600 3 ,000 [0138 ] Thus, an optimal diameter for a microparticle is Ginger extract (Gingerols , Shogaols ) 600 2 ,000 Lemon extract ( Limonene ) 500 1 ,500 between 25 - 100 microns and preferably between 45 - 75 Huperzia extract (Huperzine ) 0 . 1 0 . 3 microns. A diameter of 45 - 75 microns optimizes between minimum coating loading and a positive oral sensation ( and thus an overall positive consumption experience ) of a con US 2017 /0290768 A1 Oct. 12 , 2017 10 sumer. The ratio of core to coating ( w / w ) is between 1 : 10 to masks the taste of the encapsulating coating layer. Following 20 : 1 , preferably in the range between 2 : 1 to 5 : 1 . contact with the liquid , the encapsulation coating layer of the dietary supplement is designed not to dissolve or breakdown [0139 ] The microparticles are coated so as to be nearly ( e. g . to release its active core content) in the acidic non insoluble in the aqueous environment of the consumed enzymatic conditions of the liquid or the gel for at least 20 product , and in the mouth and esophagus of the individual minutes . This enables the microparticles to survive as a consuming it . suspension in the liquid / gel and pass through the mouth and [ 0140 ] As is described in Example 6 below , the powder esophagus without substantially releasing its contents . Once composition can include several types of particles each passed the esophagus, the composition begins to release its offering a different release trigger and a different profile of active ingredients ( in a selective and controlled manner ) in the stomach and / or the small intestines and / or in the colon , release of the active ingredient core in the GI tract ( stomach depending on the viscosity of the carrier , the properties of and below ) . the coating layer and the ( w / w ) ratio between the encapsu [ 0141] Such selective release can be effected using differ lation material and active ingredients . ent types of coating layers that are pH independent, and its [0151 ] As is mentioned hereinabove , the present compo disintegration is triggered in presence of enzymes, and sition can include more than one type of a micro particle in augmented mechanical GI tract forces a single powdered product . Different types ofmicroparticles [ 0142 ] For example , coatings that are insoluble in non can include different cores ( i. e . different active ingredient) enzymatic acidic conditions can be fabricated from coating and /or a different type of coating ( facilitating selective compositions based on Prolamin proteins ( Zein , Wheat, release of more than one active ingredient) . etc . ) , Shellac , fats (Coconut oil , Palm oil , etc . ) , and any 10152 ) For example , a single powdered dose unit can include : combination thereof. Such coatings can be used to selec (0153 ] ( a ) a microparticle facilitating rapid release of tively release the active core . ingredient X ( a dietary supplement) in the stomach [ 0143 ] Coatings dissolution in the presence of specific [0154 ] ( b ) a microparticle facilitating delayed release of digestive enzymes can be based on Gelatin , Soy proteins , ingredient Y ( a dietary supplement ) in the intestines (delay Pea proteins (Globulin ), Vegetable proteins, fats , Starches , of 15 - 120 minutes post consumption ); and Dextran , Maltodextrin , Cyclodextrin , Whey and Caseine , 10155 ] ( c ) a microparticle facilitating delayed release of ( a and any combination thereof. Such coatings can be used to dietary supplement) ingredient Z in the colon along (delay of release the active core of the micro particle in the stomach . 15 -480 minutes post consumption ) . [0144 ) Coatings dissolution in the presence of a specific (0156 ] Each micro -particle has a core with at least one digestive enzyme of the small intestines include, but not active ingredient. The active ingredient of the core can be limited to : Guar gum , gum Arabic , Pectin and Amylose , and mononuclear , multi- nuclear or incorporated in a slow - re any combination thereof. Such coatings can be used to lease or controlled release matrix . The core can also incor release the active core of the microparticle in the small porate intestinal permeability enhancing agents . intestine . [0157 ] Each microparticle can include more than one coating layer, e . g . two or more coating layers each having a [0145 ] Coatings dissolution in the presence of enzyme of different dissolvability profile . the colon include , but not limited to , Starches, Guar gum , [0158 ] A single coating layer is intended for use in bev Pectins, Chitosans , Alginates, Hydrogels , and any combina erages or other reconstructed compositions having a high tion thereof. Such coatings can be used to release the active water content . A single layer of coating is designed to core of the microparticle in the Colon . prevent the release of foul- tasting ingredients into the water 10146 ) Coatings dissolution under low pH conditions for a time period sufficient for a common consumer to include, but not limited to , Polymethacrylates . Such coatings completely consume a 330 - 500 ml serving, e . g . 20 - 30 min can be used to release the active core of the microparticle in utes . the stomach . [0159 ] A single encapsulation layer incorporating at least 10147 ) Other coatings that facilitate slow - release / con 2 coating materials each having a different dissolvability trolled release , independent of enzymatic and pH conditions profiles can be used to obtain stepwise release profiles . include , but not limited to , Ethyl Cellulose . Such coatings (0160 ] The microencapsulated active ingredients of the can be used for controlled release of an active core through present invention can also be provided in a Ready - To -Drink out the GI tract. water- soluble coatings include, but not (RTD ) beverage . In order to provide a reasonable shelf- life limited to , Methyl Cellulose . Such coatings can be used in for the RTD version , more than a single encapsulation combination with the coatings described above in order to coating layer is required . A first (and inner) encapsulation accelerate dissolution under the aforementioned conditions. coating layer can control release as described above and at [0148 ] The encapsulating layer of the microparticles can least one additional encapsulation layer can be used to seal be non -uniform to allow selective dissolution of the the core and 1st encapsulation layer from the water in the microparticles and prolonged selective release of the active RTD product . Such an outer encapsulation coating layer is ingredient. Several approaches for enabling selective release designed for maximum sealing , and is rapidly breached of active ingredients from coated microparticles are under the enzymatic and /or mechanical grinding conditions described in the Examples section which follows. of the stomach thereby exposing the inner encapsulation [0149 ] When the encapsulated microparticles are recon layer and its selective dissolution thereof . structed into a liquid -based composition , the microparticles 10161] The outer ( second ) encapsulation coating layer can are preferably suspended in the liquid and are homogenously include materials which are insoluble in acidic , non - enzy distributed therein ( e . g . not floating at the surface of the matic conditions , but are rapidly dissolved /disintegrated liquid and not settling at the bottom of the container) . under the enzymatic and /or mechanical grinding conditions [ 0150 ] The encapsulated microparticles are inert or mate of the stomach . Such materials include, but not limited to , rially inert in as far as taste and odor, or , incorporate a Prolamin proteins (Zein , Wheat , etc . ) and fats (Coconut oil , flavoring agent which masks or at the minimum materially Palm oil ) and any combinations thereof US 2017 /0290768 A1 Oct. 12 , 2017

[0162 ] Table 15 below describes release profiles of several types of products. TABLE 15 release profiles of various powders H Controlled Release In Release In Controlled Beverage / Release In Release In Release In Small Release In DGel Media Mouth Esophagus Stomach Intestines Colon Alcohol 0 % - 5 % 0 % - 2 % 0 % - 2 % 1 % - 33 % 66 % - 95 % 1 % - 33 % Metabolism Glutathione Glutathione Glutathione Glutathione Glutathione Glutathione Acceleration ALA ALA ALA ALA ALA ALA Vitamin B1 Vitamin B1 Vitamin B1 Vitamin B1 Vitamin B1 Vitamin B1 Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B2 Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B3 Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B5 Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B6 Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B9 Vitamin B12 Vitamin B12 Vitamin B12 Vitamin B12 Vitamin B12 Vitamin B12 Vitamin D Vitamin D Vitamin D Vitamin D Vitamin D Vitamin D Vitamin E Vitamin E Vitamin E Vitamin E Vitamin E Vitamin E Coenzyme A Coenzyme A Coenzyme A Coenzyme A Coenzyme A Coenzyme A Acetyl- L Acetyl- L Acetyl - L Acetyl- L Acetyl- L Acetyl - L Carnitine Carnitine Carnitine Carnitine Carnitine Carnitine NAC NAC NAC NAC NAC NAC Magnesium Magnesium Magnesium Magnesium Magnesium Magnesium Zinc Zinc Zinc Zinc Zinc Zinc Quercetin Quercetin Quercetin Quercetin Quercetin Quercetin Resveratrol Resveratrol Resveratrol Resveratrol Resveratrol Resveratrol Sulforaphane Sulforaphane Sulforaphane Sulforaphane Sulforaphane Sulforaphane Betaine / TMG Betaine/ TMG Betaine / TMG Betaine / TMG Betaine / TMG Betaine / TMG Choline Choline Choline Choline Choline Choline Glucose Glucose Glucose Glucose Glucose Glucose Cognitive & 0 % - 5 % 0 % - 2 % 0 % - 2 % 1 % - 33 % 66 % -95 % 1 % - 33 % motor Ginkgo extract Ginkgo extract Ginkgo extract Ginkgo extract Ginkgo extract Ginkgo extract Performance (Bilobalide , (Bilobalide , (Bilobalide , (Bilobalide , (Bilobalide , (Bilobalide , Recovery Gikgolides) Gikgolides ) Gikgolides ) Gikgolides ) Gikgolides ) Gikgolides ) Kudzu extract Kudzu extract Kudzu extract Kudzu extract Kudzu extract Kudzu extract (Puerarin ) ( Puerarin ) (Puerarin ) (Puerarin ) ( Puerarin ) ( Puerarin ) Lemon extract Lemon extract Lemon extract Lemon extract Lemon extract Lemon extract (Limonene ) (Limonene ) (Limonene ) (Limonene ) (Limonene ) (Limonene ) Huperzia Huperzia Huperzia Huperzia Huperzia Huperzia extract extract extract extract extract extract (Huperzine ) (Huperzine ) (Huperzine ) (Huperzine ) (Huperzine ) (Huperzine ) Ginseng Ginseng Ginseng Ginseng Ginseng Ginseng extract extract extract extract extract extract (Ginsenosides ) (Ginsenosides ) (Ginsenosides ) (Ginsenosides ) (Ginsenosides ) (Ginsenosides ) Curcumin Curcumin Curcumin Curcumin Curcumin Curcumin Nausea , pain & 0 % - 5 % 0 % - 2 % 0 % - 2 % 1 % - 20 % 20 % - 80 % 20 % - 80 % physiological Grape seed Grape seed Grape seed Grape seed White Willow White Willow discomfort extract extract extract extract Bark extract Bark extract reduction ( Proantho (Proantho (Proantho (Proantho ( Salicin ) ( Salicin ) cyanidins ) cyanidins ) cyanidins) cyanidins) Grape seed Grape seed Feverfew Feverfew Feverfew Feverfew extract extract (Parthenolides ) (Parthenolides ) ( Parthenolides ) ( Parthenolides ) (Proantho ( Proantho GingerGinger Ginger Ginger Ginger cyanidins ) cyanidins ) (Gingerols & (Gingerols & (Gingerols & (Gingerols & Feverfew Feverfew Shogaols ) Shogaols ) Shogaols ) Shogaols ) (Parthenolides ) ( Parthenolides) Ginger Ginger (Gingerols & (Gingerols & Shogaols ) Shogaols ) Gastric 0 % - 5 % 0 % - 2 % 0 % - 2 % 33 % -66 % 33 % -66 % 0 % -2 % % motility Mango extract Mango extract Mango extract Mango extract Mango extract Mango extract recovery ( Mangiferin ) ( Mangiferin ( Mangiferin ) ( Mangiferin ) ( Mangiferin ) ( Mangiferin ) Piperin Piperin Piperin Piperin Piperin Piperin

10163] The composition -of - matter of the present invention (0164 ] A composition -of - matter formulated as a drink is can be formulated as a ready - to -consume water - based drink , also served in a container which maintains at least some of shake or gel which includes any of the above described the active ingredients in powder form and isolated from the ingredients as well as colorants , thickeners , flavoring agents , liquid carrier. stabilizers and the like , or, as a powder containing the [0165 ] Thus, according to another aspect of the present microencapsulated microparticles to be reconstituted in a invention , there is provided an article of manufacturing drink or a gel prior to its consumption . which includes a container having two environmentally US 2017 /0290768 A1 Oct. 12 , 2017 12 isolated compartments , one compartment for containing Example 1 active ingredients in powder form , and the other for con taining water and optionally dissolved components such as Encapsulation of Glucose Fructose , Glucose , Betaine , Choline salt, and Creatine . [ 0166 ) FIG . 1 illustrates one such container which is 10175 ] Glucose with a pre -encapsulation diameter of 25 referred to herein as container 10 . Container 10 is preferably microns was encapsulated with a shellac - based composition . shaped as elongated cylinder 25 cm in height, 6 . 5 cm in The shellac encapsulate included 65 grams of Shellac ( SSB diameter and having a volume of 300 - 700 ml. Container 10 57 ) , 15 grams of Glycerin , 20 grams of HPMC (Vivapur can be fabricated from , but not limited to , PET or Polypro E5LV ) , 3 grams of talcum and 600 grams of water. pylene using well known approaches . Container 10 includes [0176 ] A fluidized bed was used for encapsulating the two, environmentally - isolated , compartments ( 12 and 14 ) Glucose under the following conditions: Pressure blow which are separated by partition 16 . Container 10 further back : 1 . 3 - 2 . 1 [bar ] ; Pressure pump feed : 3 .4 [bar ] ; Spraying includes an opening 18 for accessing the contents of con pressure : 2 . 5 [ bar ]; Airflow : 3 . 0 [M° per second ); Air tem tainer 10 , opening 18 can be sealed via a single use cover perature : 40 [Celsius ] . such as a pull tab , or a multi - use cover such as a screw cap . [0177 ] 150 grams ofGlucose and 75 grams of the Shellac First compartment 12 is designed for containing the com based composition ( 50 % encapsulation ) were processed via position -of -matter described herein ( e .g . the active ingredi ents of Table 2 ) , while second compartment 14 is designed 7 cycles of the following : 108 seconds of mixing with the for containing the liquid carrier (water , optionally with encapsulation composition + 600 seconds of drying the dissolved components ) . Container 10 is designed such that encapsulated Glucose without additional free encapsulate . partition 16 is breachable prior to unsealing of opening 18 [0178 ] FIG . 2 illustrates the non - encapsulated Glucose thus enabling a user to mix the components of compartment ( left image ) and Shellac -based encapsulated Glucose ( right 12 with the liquid of compartment 14 prior to consumption . image ) . [ 0167 ] Partition 16 can be breached via one of several [0179 ] Encapsulated Glucose was placed under conditions mechanisms which can be functionally connected to a lid or simulating the stomach (pH 1 . 2 ) for 30 minutes, and then cap covering opening 18 . For example , a screw cap covering under conditions simulating the small intestines (pH 6 . 8 ) . A opening 18 can be physically connected to partition 16 such D -Glucose UV Test ( R - Biopharm ) was used to analyze the that unscrewing of the screw cap breaches partition 18 . quantity of Glucose released to the surrounding media . [0168 ] In any case , once wall 16 is breached by the user, Following 30 minutes at pH 1 . 2 (stomach ) , 10 % of the the container can be vigorously shaken in order to dissolve Glucose was released to the surrounding media . At pH 6 . 8 and / or suspend the active ingredients in the water prior to ( intestines ) , all the remaining Glucose was released to the consumption . surrounding media following 40 minutes . [ 0169 ] Thus , the present invention provides a composi tion - of- matter which can be used to counteract the negative Example 2 effects of alcohol consumption in a rapid and timely manner. [ 0170 ] The composition of the present invention concur Accelerating Alcohol Catabolism in Human rently and timely addresses three key aspects of excess Subjects alcohol consumption by providing effective alcohol catabo lism , improvements in motor, cognitive, attention , task [ 0180 ] A study on 19 participants ( 9 males and 10 females , switching, quality decision making and reduced risk taking ages 21- 29 ) , evaluated the increase in alcohol catabolism behavior; and improvements in physiological sensations / between control (no dietary supplements ) and study arm feeling . Since the present composition can include relatively (with the composition of matter ) after each of the partici large quantities of water it also provides a beneficial rehy pants consumed 500 cc of beer with 4 . 9 % alcohol ( e . g . 24 . 5 dration effect along with large quantities of active ingredi cc of pure alcohol ). Table 16 below summarizes the findings . ents . [ 0171] The present composition was designed for con TABLE 16 sumption following ( e . g . after) alcohol uptake so as to not Diff influence the desired positive effects of alcohol consumption Control Composition BAC % /h from the consumer' s subjective perception . However , con Blood 30 m - End 30 m - End 30 m - End sumption of the present composition prior to and / or concur # Gender Volume BAC % / h BAC % / h rently with , alcohol consumption , would prevent blood M 6 ,160 0 .015 % 0 .027 % 79 % alcohol levels from peaking and thus would prevent or at 5 , 313 0 . 012 % 0 .021 % 80 % least reduce motor and cognitive performance from degrad 3 , 243 0 .017 % 0 .018 % 7 % ing. 4 , 221 0 .009 % 0 .016 % 81 % 5 , 498 0 .011 % 0 .015 % 31 % [ 0172 ] As used herein the term “ about” refers to + 10 % . 6 , 391 0 . 011 % 0 . 016 % 46 % [ 0173 ] Additional objects, advantages , and novel features 4 , 134 0 .009 % 0 . 015 % 62 % of the present invention will become apparent to one ordi 3 ,685 0 .019 % 0 . 022 % 18 % narily skilled in the art upon examination of the following 4 , 020 0 .018 % 0 .029 % 63 % examples , which are not intended to be limiting . 4 ,620 0 .014 % 0 . 018 % 35 % auAWNEOOvaAWNA 5 ,082 0 .011 % 0 . 019 % 66 % 4 , 221 0 . 018 % 0 .022 % 25 % EXAMPLES 3 , 450 0 . 013 % 0 . 019 % 47 % 4 ,620 0 . 010 % 0 . 015 % 48 % [0174 ] Reference is now made to the following examples, 5 ,621 0 . 011 % 0 . 023 % 101 % which together with the above descriptions, illustrate the 5 , 226 0 .013 % 0 . 022 % 71 % invention in a non limiting fashion . US 2017 /0290768 A1 Oct. 12 , 2017

TABLE 16 -continued impulse control between placebo (dietary supplements with no effect on motor , cognitive and impulse control perfor Diff mance ) and the present composition of matter . The placebo Control Composition BAC % / h Blood 30 m - End 30 m - End 30 m - End and composition sessions were scheduled at least 7 days Gender Volume BAC % / h BAC % / h apart to avoid interference between the sessions. [ 0185 ) For the purpose of the study , the following motor 17 3 ,685 0 . 017 % 0 . 017 % 0 % 18 3 ,685 0 .012 % 0 .014 % 22 % and cognitive studies from the Lumosity web site were used : 19 M 4 , 312 0 .015 % 0 . 019 % 31 % [0186 ] Speed Match Overdrive ( testing information pro 20 cessing and memory ) General [0187 ] Color Match ( testing response inhibition ) Average 0 .013 % 0 .019 % 48 % [0188 ] Birds in Migration ( testing selective attention ) Median 0 .013 % 0 .019 % 47 % [0189 ] Ebb and Flow (testing task switching) SD 0 . 003 % 0 . 004 % 28 % [0190 ] Each participant trained on each test for at least 3 P -value 0 . 00000 hours to reach the highest level of self - proficiency and Males performance in order to avoid a learning curve during the Average 0 .012 % 0 . 019 % 57 % study itself . Median 0 . 011 % 0 .019 % 48 % [0191 ] Prior to the consumption of alcohol, participants SD 0 . 002 % 0 .004 % 25 % performed each test 5 times , to record the baseline perfor Females mance for the specific day of testing . The 5 results were Average 0 . 015 % 0 . 019 % 40 % averaged to obtain a calculated score for each test . Median 0 .015 % 0 .019 % 36 % [0192 ] After each participant consumed an alcohol quan SD 0 . 004 % 0 .004 % 29 % tity calculated to bring his /her blood alcohol level to 0 . 1 % , every 15 minutes , a blood alcohol level was measured for 10181] The median alcohol catabolism rate was 0 .019 % /h each participant (using the BACtrack S75 breathalyzer ) in the composition - treated individuals vs. 0 . 013 % / h in the which then performed the battery of cognitive tests from the control army, a 47 % advantage ( p = 0 .00000 ) . In men , the Lumosity web site . At 45 minutes following the end of median alcohol catabolism rate was 0 .019 % / h in the com alcohol consumption , each participant consumed either the position - treated individuals vs . 0 .011 % / h in the control arm , placebo composition or the present composition . ( Partici a 48 % advantage . In women , the median alcohol catabolism pants were told the Placebo composition was an effective rate in the composition study was 0 . 019 % / h in the compo composition ) . Each session ended 3 . 5 hours following the sition - treated individuals vs . 0 .015 % / h in the control arm , a completion of alcohol consumption . 36 % advantage . 10193 ] All 4 tests demonstrated advantage of the study composition arm over the placebo arm . As the 4 tests Example 3 evaluated information processing +memory ; inhibition , selective attention ; and ; task switching , it can thus be Increasing Motor and Cognitive Performance in concluded that the present composition is effective in Human Subjects improving motor and cognitive performance in individuals [0182 ] A 53 years old male , who does not frequently under the influence of high blood alcohol ( above 0 .08 % ) . consume alcohol and weighs 85 kg , fasted for 2 hours prior [0194 ] Tables 17 and 18 below present response time and to consuming 59 grams of alcohol ( 71 cc of 96 % alcohol) normalized result ( response time divided by accuracy % , admixed with 160 cc of Cold Forrest berries ' juice . It took generating a value representing response time in millisec the individual 20 minutes to consume the liquid . Twenty onds at 100 % accuracy ) of placebo and present composition . minutes following consumption , the participant consumed a The comparison time points , 15 minutes and 45 minutes , composition of matter which included dietary supplements were measured from the time the participant started con selected for improving motor and cognitive functions . suming the dietary supplements : [0183 ] The cognitive and motor functions of the individual were evaluated using a ' lost in migration test (FIG . 3 ) , TABLE 17 decision making ' test ( FIG . 4 ) , “ spatial' test (FIG . 5 ) and Comparison between placebo and the present ' speed test (FIG . 6 ) using standard techniques . As is shown composition - reaction time (ms ) by the table data and graphs of these Figures , the present 15 minutes after 45 minutes after composition significantly reduced the time it took the indi supplements supplements vidual to return to normal function , when compared to a consumption consumption control without the composition . In addition , the decline in performance after consuming the composition was lower Composi Composi when compared to the control. Placebo tion D iff . Placebo tion Diff . Speed Match 664 645 19 650 630 20 Example 4 Overdrive Color Match 667 653 14 663 639 24 Birds in 665 645 20 660 640 20 Improving Motor , Cognitive and Impulse Control Migration in a Group of Participants Under the Influence of Ebb & Flow 580 568 12 575 562 13 High Blood Alcohol [ 0184 ] A study on 24 participants (12 males and 12 The Diff . represents the advantage ( or disadvantage ) of the females05: 42 ,, Angonoages y21 -29en ) , evaluatedel censo motor en , e cognitivese andmom theresponse one thingtime in the headComposition nerales study vsdevantage. the Placebo to US 2017 /0290768 A1 Oct. 12 , 2017 14 study . ( All values in the table are in Milliseconds ) . As can be [0209 ] At the first 10 minute time mark , no release of viewed from the table above , there is a consistent advantage Vitamin B2 was observed . After 20 min , ~ 7 % was released in response time in the Composition study vs. the Placebo to the surrounded media . After 30 min , ~ 15 % was released . study . After 60 and 120 minutes no further release was observed (FIG . 7 ) . TABLE 18 Example 6 Comparison between placebo and the present composition - normalized results Powders Having More Than One Microparticle 15 minutes after 45 minutes after Type supplements supplements consumption consumption Composition - of- Matter 1 Composi Composi [0210 ] This composition -of -matter includes the two Placebo tion Diff . Placebo tion Diff . microparticle types shown in FIGS. 8a - b . Speed Match 738 70731 707684 23 [0211 ] The microparticle in FIG . 8a has a core ( A ) with a Overdrive diameter of 50 microns , and a coating layer ( B ) 5 microns Color Match 738738 744 - 6 745 723723 22 thick , bringing the final diameter of the particle to 60 Birds in 724 70519731705705 731 705 26 microns. The particle of FIG . 8a includes a Ginger -extract Migration active core surrounded by a zein - based coating layer. The Ebb & Flow 629 614 15 635 6 15 20 coating layer of this particle is designed to be materially insoluble in non - enzymatic acidic conditions of the bever The Diff . value represents the advantage ( or disadvantage ) age , and to rapidly dissolve in the enzymatic conditions of of the response time in the Composition study vs . the the stomach . Placebo study. (All values in the table are in Milliseconds [0212 ] The particle of FIG . 8b has a core ( C ) with a representing response time @ theoretical 100 % response diameter of 55 microns, and a coating layer ( D ) 5 microns accuracy ) . As can be viewed from the table above , except in thick , bringing the final diameter of the particle to 65 a single measurement, there is a consistent advantage in microns. The particle is FIG . 8b includes a Ginger extract response time in the Composition study vs . the Placebo active core surrounded by a coating layer of Shellac + HPMC . study . The coating layer of this particle is designed to be materially insoluble in the non -enzymatic acidic conditions of the Example 5 beverage , materially insoluble in the acidic enzymatic con ditions of the stomach , and to gradually dissolve in the Acidic Water Resistant Micro -Encapsulation of enzymatic and pH conditions of the small intestines . Vitamin B2 ( Core ) in Zein [0213 ] A composition - of- matter including these two [ 0195 ] An experiment was conducted in order to test the microparticle types enables rapid release of the Ginger release profile of encapsulated vitamin B2 in an enzyme extract ( from the particle in FIG . 8a ) in the stomach thereby free , acidic environment simulating the conditions of a positively affecting local recovery of gastric motility beverage (after reconstruction of the powdered composi through Ginger' s 5 -HT3 antagonistic properties , and to tion ). facilitate rapid absorption of Ginger constituents starting in [0196 ]. Vitamin B2 was encapsulated with a prolamine the Duodenum for affecting brain receptor in the alleviation based coating . Prolamine proteins are water- insoluble, and of nausea and vomiting . The later release of the Ginger edible ( food -grade ). extract ( from the particle in FIG . 8b ) in the small intestines [0197 ] A mini ( lab -scale ) spray dryer Buchi B -290 starting from the Jejunum facilitates the continuation of equipped with an advanced inert loop under nitrogen was Ginger constituents absorption and maintenance of its anti used to encapsulate the Vitamin B2 with a 3 - fluid Buchi emetic brain properties, nozzle under the following conditions : [0198 ] 20 g of Vitamin B2 were dispersed in 80 g of Composition - of- Matter 2 ethanol (or water ) [0214 ] This composition -of - matter includes the three [ 0199 ] 15 g of Zein protein was dissolved in an 80 g microparticle types shown in FIGS. 9a -C . ethanol + 20 % water solution [0215 ] The microparticle of FIG . 9a has a core (E ) with a [0200 ] Parameters of spraying : diameter of 50 microns , and a coating layer ( F ) 10 microns thick , bringing the final diameter of the particle to 70 [0201 ] Inlet temp: 1100C microns . The particle in FIG . 9a includes Ginger extract and [0202 ] Outlet temp: 750C Piperin in the active core surrounded by a coating layer [0203 ] Aspirator: 100 % /35 m3/ h which includes Zein and a Cellulose derivative . The coating [0204 ] Feed rate core / shell : 5 ml/ min / 10 ml/ min layer of this particle is designed to be materially insoluble in [ 0205 ] Spray gas flow : 50 mm non - enzymatic acidic conditions of the beverage , and to [ 0206 ] Particle size : d90 20 microns rapidly dissolve in the enzymatic conditions of the stomach . 02071. The final product was collected and placed under (0216 The microparticle of FIG . 9b has a core ( G ) with a condition simulating the enzyme- free acidic condition of the diameter of 60 microns, and a coating layer ( H ) 7 . 5 microns reconstructed beverage (only acid 1 . 1 % ) . thick , bringing the final diameter of the particle to 75 [0208 ] The Vitamin B2 was tested in a spectrophotometer microns. The particle is FIG . 9b includes Ginger extract and Perkin ELMER LAMBADA 25 at wavelength 268nanome- Piperin as the active core , surrounded by a coating layer ter that is typical for Vitamin B2 absorbance . which includes Zein and Shellac . The coating layer of this US 2017 /0290768 A1 Oct. 12 , 2017 15 particle is designed to be materially insoluble in the non [0222 ] The particle of FIG . 10c has a core ( 0 ) with a enzymatic acidic conditions of a beverage , materially diameter of 45 microns, and a coating layer ( P ) 5 microns insoluble in the acidic enzymatic conditions of the stomach , thick , bringing the final diameter of the particle to 55 and gradually dissolve in the enzymatic and pH conditions microns. The particle of FIG . 10c includes White Willow of the small intestines . Bark extract (Salicin ) as the active core , surrounded by a [ 0217 ]. The microparticle of FIG . 9c has a core ( I ) with a coating layer including Alginate and Starch . The coating diameter of 45 microns, and a coating layer ( J ) 7 . 5 microns layer of this particle is designed to be materially insoluble in thick , bringing the final diameter of the particle to 60 the non - enzymatic acidic conditions of the beverage , mate microns. The particle of FIG . 9c includes a Ginger extract rially insoluble in the acidic enzymatic conditions of the active core surrounded by a coating layer which includes stomach , materially insoluble in the enzymatic and pH cross - linked Alginate . The coating layer of this particle is conditions of the small intestines , and , gradually dissolve in designed to be materially insoluble in the non - enzymatic the enzymatic and pH conditions of the Colon . acidic conditions of the beverage , materially insoluble in the [0223 ] A composition -of - matter including these three acidic enzymatic conditions of the stomach , materially microparticle types enables rapid release of Mangiferin insoluble in the enzymatic and pH conditions of the small ( from the microparticle in FIG . 10c ) in the stomach posi intestines , and , gradually dissolve in the enzymatic and pH tively affecting local recovery of gastric motility of the conditions of the Colon . stomach through Mangiferin ’ s 5 -HT4 agonistic properties [0218 ] A composition -of - matter including these three and facilitating rapid activation of intestinal 5 -HT4 receptors microparticle types enables rapid release of the Ginger by Mangiferin starting in the Duodenum . The later release of extract and the Piperin (from the particle in FIG . 9a ) in the the Mangiferin and Salicin ( from the microparticle in FIG . stomach positively affects local recovery of gastric motility 106 ) in the small intestines starting from the Jejunum through Ginger 's 5 -HT3 antagonistic properties and Piper facilitates the continuation of Mangiferin ' s impact on the in ' s TRPV1 agonistic properties , and to facilitate rapid recovery of intestinal motility and Salicin ' s intestinal absorption of Ginger constituents starting in the Duodenum absorption and antagonistic action on the brain ' s 5 -HT2 for affecting brain receptor in the alleviation of nausea and receptors , alleviating pain and headache , The targeted vomiting ; and ; to facilitate Piperin ' s intestinal absorption Colonic release of the Salicin ( from the microparticle of enhancement properties . The later release of the Ginger FIG . 10c) further facilitates its continued availability in the extract and Piperin ( from the particle in FIG . 9b ) in the small brain and anti - headache/ migraine action . In summary , this intestines starting from the Jejunum facilitates the continu composition , with its 3 coating implementations, combines ation of Ginger constituents absorption and maintenance of rapid recovery of gastric motility , and facilitation and main its anti -emetic brain properties; and ; Piperin ' s continued tenance of up to 8 hours of alleviating pain , headache and / or enhancement of intestinal absorption , The targeted Colonic or migraine sensations . release of the Ginger extract ( from the particle of FIG . 9c ) further facilitates its continued availability in the brain and Composition - of- Matter 4 anti - emetic action . In summary , this composition combines [0224 ] This composition -of - matter was designed for a rapid recovery of gastric motility , enhancement of intestinal shelf life of over 3 months after reconstruction into an absorption and facilitation and maintenance of up to 8 hours orally - deliverable gel. This composition is manufactured of alleviating nausea and /or or vomiting sensations. using a spray dryer with a 4 - fluid injector, where 3 of the 4 channels are fed with fluids and / or melted fat , and single Composition - of- Matter 3 channel is utilizing air or Nitrogen , as applicable . [0219 ] This composition -of - matter includes the three [0225 ] This composition -of - matter includes the three microparticle types shown in FIGS. 10a - C . microparticle types shown in FIGS. 11a - c . [0220 ] The microparticle of FIG . 10a has a core ( K ) with [0226 ] The microparticle of FIG . 11a has a core ( Q ) with a diameter of 55 microns, and a coating layer ( L ) 5 microns a diameter of 40 microns, a first and inner coating layer ( R ) thick , bringing the final diameter of the particle to 65 10 microns thick , bringing the diameter of the particle to 60 microns. The microparticle in FIG . 10a includes a Man microns and a second and outer coating layer ( S ) 5 microns giferin active core surrounded by a coating layer which thick , bringing the final diameter of the particle to 70 includes fat and Cellulose . The coating layer of this particle microns . is designed to be materially insoluble in non - enzymatic 02271. The microparticle of FIG . 11a includes Ginger acidic conditions of the beverage , and to to rapidly dissolve extract and Piperin as the active core surrounded by an inner in the enzymatic conditions of the stomach . coating layer including Zein and a Cellulose derivative , and [ 0221] The particle of FIG . 106 has a core (M ) with a an outer coating layer including Gelatin and fat ( Carnauba , diameter of 50 microns , and a coating layer ( N ) 5 microns Stearic acid , Sunflower ). The outer coating layer improves thick , bringing the final diameter of the particle to 60 the impermeability of the particle to acidic water and / or microns . The particle of FIG . 10b includes Mangiferin and dissolution in acidic water - containing gel (thus providing White Willow Bark extract (Salicin ) as the active core longer shelf- life ), but is quickly dissolvable in the enzymatic surrounded by a coating layer including Ethyl Cellulose , conditions of the stomach . The inner coating layer of this MCG Medium Chain Glycerides ) and Oleic Acid . The particle is designed to be materially insoluble in non coating layer of this particle is designed to be materially enzymatic acidic conditions of the gel , and to rapidly insoluble in the non - enzymatic acidic conditions of the dissolve in the enzymatic conditions of the stomach . beverage, materially insoluble in the acidic enzymatic con [0228 ] The microparticle of FIG . 11b has a core ( T ) with ditions of the stomach , and to gradually dissolve in the a diameter of 50 microns , a first and inner coating layer ( U ) enzymatic and pH conditions of the small intestines . 10 microns thick , bringing the diameter of the particle to 60 US 2017 /0290768 A1 Oct. 12 , 2017 microns and a second and outer coating layer ( V ) 5 microns a single embodiment, may also be provided separately or in thick , bringing the final diameter of the particle to 70 any suitable sub - combination . microns . [0234 ] Although the invention has been described in con [0229 ] The microparticle of FIG . 11b includes Ginger junction with specific embodiments thereof, it is evident that extract and Piperin as the active core surrounded by an inner many alternatives, modifications and variations will be coating layer including Zein and Shellac , and an outer apparent to those skilled in the art . Accordingly , it is coating layer including Gelatin and fat ( Carnauba , Stearic intended to embrace all such alternatives, modifications and acid , Sunflower ). The outer coating layer improves the variations that fall within the spirit and broad scope of the impermeability of the particle to acidic water and/ or disso appended claims. All publications , patents and patent appli lution in acidic water- containing gel ( thus providing longer cations mentioned in this specification are herein incorpo shelf - life ) , but is quickly dissolvable in the enzymatic con rated in their entirety by reference into the specification , to ditions of the stomach . The inner coating layer of this the same extent as if each individual publication , patent or particle is designed to be materially insoluble in the non patent application was specifically and individually indi enzymatic acidic conditions of the gel, materially insoluble cated to be incorporated herein by reference . In addition , in the acidic enzymatic conditions of the stomach , and to citation or identification of any reference in this application gradually dissolve in the enzymatic and pH conditions of the shall not be construed as an admission that such reference is small intestines. available as prior art to the present invention . [ 0230 ] The microparticle of FIG . 11c has a core ( W ) with 1 . A composition -of - matter comprising at least two types a diameter of 45 microns , a first and inner coating layer ( X ) ofmicroparticles each formed from an active ingredient core 5 microns thick , bringing the diameter of the particle to 55 encapsulated by at least one coating layer incorporating at microns and a second and outer coating layer ( Y ) 5 microns least one coating material , said at least two types of said thick , bringing the final diameter of the particle to 65 microparticles being differentiated by said active ingredient microns. or said at least one coating material . [0231 ] The microparticle of FIG . 11c includes a Ginger 2 . The composition - of -matter of claim 1 , wherein each of extract active core surrounded by an inner coating layer of said at least two types of said microparticles is capable of cross -linked Alginate and an outer coating layer of Gelatin releasing said active ingredient at a different region of a GI and fat (Carnauba , Stearic acid , Sunflower ) . The outer tract. coating layer improves the impermeability of the particle to 3 . The composition -of - matter of claim 1 , wherein said acidic water and / or dissolution in acidic water - containing microparticles have a diameter of 25 -100 microns . gel (thus providing longer shelf - life ) , but is quickly dissolv 4 . The composition -of - matter of claim 1 , wherein said able in the enzymatic conditions of the stomach . The inner microparticles include one or more active ingredients coating layer of this particle is designed to be materially selected from the group consisting of: insoluble in the non - enzymatic acidic conditions of the gel, ( a ) a dietary supplement affecting motor and cognitive materially insoluble in the acidic enzymatic conditions of performance ; the stomach , materially insoluble in the enzymatic and pH ( b ) a dietary supplement having anti- gastroparesis , anti conditions of the small intestines , and gradually dissolve in emetic , analgesic and anti - inflammatory activities ; and / the enzymatic and pH conditions of the Colon . or [0232 ] A composition -of - matter including these three (c ) a dietary supplement capable of increasing alcohol microparticle types enables rapid release of the Ginger catabolism . extract and the Piperin ( from the microparticle of FIG . 11a ) 5 . The composition -of - matter of claim 4 , wherein said in the stomach positively affects local recovery of gastric microparticles comprise ( a ) and (b ) , (b ) and ( c ) or ( a ) and motility through Ginger' s 5 -HT3 antagonistic properties and (c ) . Piperin ’ s TRPV1 agonistic properties , and facilitating rapid 6 . A beverage , shake or gel comprising a dispersion of the absorption of Ginger constituents starting in the Duodenum composition -of - matter of claim 1 in an aqueous medium . for affecting brain receptor in the alleviation of nausea and 7. The beverage of claim 6 , wherein a pH of said beverage vomiting and facilitating Piperin ' s intestinal absorption is 2 . 4 - 3 . 5 . enhancement properties . The later release of the Ginger 8 . The composition -of - matter of claim 4 , wherein said extract and Piperin ( from the microparticle in FIG . 11b ) in dietary supplement affecting motor and cognitive perfor the small intestines starting from the Jejunum facilitates the mance is selected from a group consisting of Bilobalide , continuation ofGinger constituents absorption and mainte Ginkgolides ( A , B & C ), Puerarin , Resveratrol, Quercetin , nance of its anti - emetic brain properties and Piperin ' s con Curcumin , Caffeine , Theophylline , Amentoflavone , Dihy tinued enhancement of intestinal absorption . The targeted dromyricetin , Copper Glycinate Chelate , Huperzine A , Ros Colonic release of the Ginger extract( from the microparticle marinic acid , Parthenolides, Salicin , Eriodictyol , Alpha of FIG . 11c ) further facilitates its continued availability in Lipoic Acid , 1 - Cysteine, N - Acetyl - Cysteine , Magnesium , the brain and anti - emetic action . In summary , this compo Zinc, Amentoflavone , Adiantum venestum , Amaranthus sition , with its 3 coating implementations, combines rapid virdis , Houttuynia cordata , Minthostachys mollis , Sargas recovery of gastric motility , enhancement of intestinal sum fusiforme, Usnea florida , Limonene , Proanthocyani absorption and facilitation and maintenance of up to 8 hours dins, Zinc, Sulforaphane , Menthol, Gingerols , Shogaols and of alleviating nausea and / or or vomiting sensations. Parthenolides . [0233 ] It is appreciated that certain features of the inven 9 . The composition -of -matter of claim 4 , wherein said tion , which are , for clarity , described in the context of dietary supplement affecting motor and cognitive perfor separate embodiments ,may also be provided in combination mance is selected from a group consisting of Bilobalide, in a single embodiment . Conversely , various features of the Huperzine A , N - Acetyl- Cysteine , L -Carnitine , Acetyl- L invention , which are , for brevity, described in the context of Carnitine , Glutamic acid , Glycine , L -Glutamate , L - Aspar US 2017 /0290768 A1 Oct. 12 , 2017 17

tate , L - Alanine, Magnesium salt, Zinc salt, Polygala Limo- is selected from a group consisting of Quercetin , Caffeine , nene , Tenuifolia , Acorns gramineus , Poria cocos, Limonene , Theophylline, Curcumin , Sulforaphane, Eriodictyol, Gingerols , Shogaols , Sulforaphane , Betaine , L - Cysteine and Betaine / TMG , L -Cysteine , N - Acetyl- Cysteine and Pyruvate Mangiferin . salt . 10 . The composition -of - matter of claim 4 , wherein said dietary supplement having anti - gastroparesis , antiemetic , 14 . An article of manufacturing comprising a container analgesic and anti- inflammatory activities is having two environmentally isolated compartments, a first selected from a group consisting of Curcumin , Thunder compartment including the composition - of- matter of claim God Vine , Resveratrol, Quercetin , Kaempferol, Pycog 1 and a second compartment including a liquid . enol, Parthenolides , EGCG , Ursolic acid , Berberine , 15 . The article ofmanufacturing of claim 14 , wherein said Ginsenosides , gingerols , shogaols , Salicin and Hespe container is constructed so as to enable mixing of said ridin , Vitamin C , Mangosteen , and Butterbur. composition -of -matter with said liquid to generate a con 11 . The composition -of - matter of claim 4 , wherein said sumable suspension . dietary supplement having anti - gastroparesis , antiemetic , 16 . The article of manufacturing of claim 14 , wherein the analgesic and anti- inflammatory activities is selected from a composition - of- matter includes at least one active ingredient group consisting of Shogaols , Piperin , Magnesium salt , Zinc selected from the group consisting of Bilobalide , Gink salt , Omega - 3 , Achinacea , Carvone, Camphor, Mustard oil golides, Amentoflavone, Dihydromyricetin , Puerarin , Limo and Carnosol . nene, Huperzine, Quercetin , White Willow Bark , Feverfew , 12 . The composition -of - matter of claim 4 , wherein said Grape Seed Extract , Alpha Lipoic Acid and Co - Enzyme A . dietary supplement capable of increasing alcohol catabolism is selected from a group consisting of B Vitamins: 1 , 2 , 3 , 5 , 17 . The composition -of - matter of claim 1 , wherein said at 6 , 9 and 12 , Pantethine , Vitamin D , Vitamin E , TMG ( Be least one coating material is selected from the group con taine ) , Choline salt , Zinc salt, SAMe, Nicotinamide , Folate ! sisting of HPMC , HPMPC , Carbomers , PEGs, Prolamin Folic acid , Alpha Lipoic Acid , proteins ( Zein , Wheat, etc . ), Shellacs, fats (Coconut oil , Co - enzyme A , Proanthocyanidines , Cysteinylglycine, Palm oil , Carnauba wax , Stearic acid , Sunflower oil ) , Gela Magnesium salt , Sulforaphane , L -Cysteine , N - Acetyl tin , Soy proteins, Pea proteins (Globulin ), Vegetable pro Cysteine , Resveratrol, Quercetin , Caffeine , Theophyl teins, Starches , Dextran , Maltodextrin , Cyclodextrin , Whey , line, L - Carnitine, Acetyl- L - Carnitine, Pyruvate salt, Caseine, Guar gum , gum Arabic , Pectin , Amylose , Pectins , Fructose , Bilobalide, Puerarin , Shogaols , Salicin , Sul Chitosans, Alginates, Hydrogels , HMPC , HPMPC , PVA , foraphane , Menthol, Curcumin and Sulforaphane . PEGs, Carbomers, Polymethacrylate , Ethyl Cellulose and 13 . The composition -of - matter of claim 4 , wherein said Methyl Cellulose . dietary supplement capable of increasing alcohol catabolism * * * * *